

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/06250 A2

(51) International Patent Classification⁷: G01N 33/00

(21) International Application Number: PCT/US00/19383

(22) International Filing Date: 18 July 2000 (18.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/144,579 19 July 1999 (19.07.1999) US
09/453,122 2 December 1999 (02.12.1999) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US Not furnished (CIP)
Filed on Not furnished

(71) Applicant (for all designated States except US): THE ALTHEXIS COMPANY, INC. [US/US]; 1365 Main Street, Waltham, MA 02451-1624 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CONNELLY,

Patrick, R. [US/US]; 15 Lovers Lane, Harvard, MA 01451 (US). ALI, Janid, Asghar [GB/US]; Seven Dolores Road, Waltham, MA 02452 (US). BRUZZESE, Frank, Joseph [US/US]; 84 Prince Street, Boston, MA 02113-1711 (US). FAERMAN, Carlos, H. [CA/US]; 41 Mohawk Drive, Acton, MA 01720 (US).


(74) Agents: ALTHERR, Robert, F. et al.; Banner & Witcoff, Ltd., 11th floor, 1001 G Street, N.W., Washington, DC 20001-4597 (US).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: THERMO-CHEMICAL SENSORS AND USES THEREOF



(57) Abstract: Methods described herein link the binding event of a test ligand, or a substrate, to a target (e.g., a target protein) to the generation of a heat output. Methods of the present application can be used to screen for pharmaceutical agents.

WO 01/06250 A2



Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

THERMO-CHEMICAL SENSORS AND USES THEREOF

Related Applications

5 This application claims the benefit of Provisional Application No. 60/144,579 filed July 19, 1999, which is hereby incorporated by reference.

Field of the Invention

10 The invention relates to the use of a thermo-chemical sensor, e.g., a calorimeter, to screen for ligands or substrates.

Background of the Invention

Random screening (e.g., testing for activity) of natural products and synthetic chemical databases is a powerful method for discovering compounds which interact with target biomolecules of interest. Identification of substances that interact with target biomolecules is often a crucial step, and typically a prerequisite, for drug discovery. Substances that interact with biomolecules are referred to as ligands. Ligands can be divided into two main categories: binding ligands, which bind and form stable complexes with target biomolecules; and substrates, which interact with target biomolecules and become chemically modified. Ligands for a biomolecular target can be identified by their ability to physically associate with the target biomolecule. The processes of binding and substrate turnover are typically probed by assays that indicate if complex formation or chemical reactivity has occurred or not. These assays often depend on changes in, for example, spectroscopic or chromatographic properties of the complex or ligands of interest.

Large-screening assays can be limited in their utility in a number of ways. For example, the vast number of possible ligands which can be searched for a given target protein represents a daunting task, especially when the function of the target is unknown. Enzyme assays, in particular, require knowledge of target function to select suitable substrates that enable screening. Screening compounds that interact with targets of unknown function has been recently emphasized as a result of efforts to sequence the genomes of various organisms. For instance, in the field of microbiology, the complete genomes of at least fifteen species of bacteria and fungi have been sequenced. These sequence data have led to the identification of many new potential protein targets for new antimicrobial agents. Particularly attractive targets for antibacterial drug discovery are those that are indispensable for bacterial growth, yet have no counterpart in eukaryotes. As

many of these potential targets have no known function, they are effectively intractable for drug discovery programs that rely on large scale screening assays.

In addition to the limitation on assays for targets of unknown function, many screening assays measure the interaction between a compound and a target in a way that limits the scope of the compounds that can be tested. For example, although many proteins have multiple functions, most assays are capable of detecting only one of such functions. Such assays limit the scope of the compounds that can be tested. Additional limitations to currently available screening assays include: (i) length and/or costly separation steps that are often necessary in non-homogeneous assays; (ii) problems of optical detection associated with assays that cannot effectively detect the activities of colored compounds or suspensions or turbid extracts; (iii) the tedious and cumbersome testing of even a small subset of possible compounds when the assays are not high-throughput assays; (iv) the expense and difficulty of assays that require the use of cell lines and/or animals; and (v) the absence of information obtained in most currently available assays about the strength of an interaction between the test compound and the target.

Accordingly, there is a need for relatively inexpensive, large-scale assays which enable the detection of an interaction between a target and a test compound, without significantly limiting the scope of the target functions that can be detected.

Summary of the Invention

Methods described herein link the interaction, e.g., binding, of a test compound, e.g., a test ligand or a test substrate, with a target (e.g., a target protein or nucleic acid) to a change in heat. The heat output is detected by calorimetry. This allows analysis of the interaction without imposing sharply constraining limitations on the type, range, or specific identity of the activity of the target. By way of example, it allows for the identification of an interactor, e.g., a substrate, for a target having an unknown, poorly characterized, or merely putative or broadly described activity. E.g., where the target is an enzyme, methods of the invention detect a change in heat generated upon conversion of a test substrate(s) into a product(s) or, where the target and interactor are ligand and counter-ligand, upon binding. The absorption or evolution of heat is a universal property of chemical reactions, thus the power of the methods of the invention can transcend that of methods which make overly constraining limiting assumptions about the nature of the target or its interactions with other molecules. Some embodiments of the invention require no assumptions

about the nature of the target and its interaction with its interactor, e.g., its naturally occurring ligand, substrate, or binding partner. Other methods of the invention incorporate knowledge of or assumptions about the target (and/or interactor) to guide in the choice of potential interactors. E.g., embodiments of the invention use genomic, or other bioinformatic analyses of the target to
5 optimize and prioritize the choice of interactors against which to test the target.

Accordingly, in one aspect, the invention features, a method of analyzing a target, e.g., a protein. (Although the method is described with regard to a protein, other target molecules, e.g., other macromolecules, e.g., nucleic acids, can be analyzed with the methods described herein.)

10 The method includes:

(1) optionally, assigning a putative function to the target, e.g., protein. Putative function can be assigned by any means, e.g., by the identification of a characteristic possessed (or in some cases not possessed) by the target. Exemplary characteristics include: a structural characteristic, e.g., in the case of a protein, a preselected level of sequence identity with another
15 protein; possession of a sequence or motif, or a protein fold; similarities in 3-dimensional structure between the target and another molecule, e.g., a protein of known function; promoter structure or other 3', 5', or other regulatory structure; chromosomal location or other genetic properties such as suppressor, auxotroph, permease, drug resistance, drug sensitivity, or other similar activities or properties; expression profile, e.g., tissue specificity, disease, or disorder specific expression,
20 temporal expression pattern; source, e.g., the species from which the target is derived. The identification of a characteristic shared (or in some cases not shared) by the target and a molecule, e.g., a protein, of known function can allow assignment of the, or an, activity of the molecule, e.g., protein, of known function to the target. For example, putative function can be assigned, e.g., by comparing the sequence of the protein, or a nucleic acid which encodes it, to a reference sequence,
25 (e.g., determining if the target protein includes a preselected sequence, e.g., a preselected motif, e.g., a consensus sequence), or by comparing the sequence of the protein to another protein with known 3-dimensional structure (e.g., determining the presence or absence of a protein fold); or by comparing the 3-dimensional structure of a crystal of the target protein to other proteins of known function;

30 (2) providing a library of interaction candidates, e.g., a library of potential substrates, or binding ligands, for a protein. (Preferably the library will include at least one, and more preferably

a plurality of members, each of which is known to interact with a protein having the assigned putative function. By way of example, a library can contain a plurality of protease substrates. Assignment of putative function can optimize screening strategy, e.g., by guiding the choice of a particular library of interactors.);

- (3) providing a reaction mixture which includes the target, e.g., protein:
- (4) contacting the target, e.g., protein, with a member of the library,
- (5) evaluating a change in heat output of the reaction mixture;
- (6) optionally, comparing the value for heat change obtained with a predetermined value,

thereby analyzing the target, e.g., protein, e.g., by identifying a library member which is a substrate or a ligand of the target, e.g., protein. (In this method, as well as with all other methods described herein the assignment of letters or numbers to the steps of a method is merely for the convenience of the reader and, unless otherwise required, does not mean that the steps must be performed in the recited order.)

In a preferred embodiment, the target, e.g., a protein, is produced by a pathogen, e.g., a prokaryotic or a eukaryotic pathogen, including a bacterium, a protozoan, a virus, e.g., phage, or a fungus. For example, the protein can be a protein produced by any of the following species: *Aquifex aeolicus*, *Pyrococcus horikoshii*, *Bacillus subtilis*, *Treponema pallidum*, *Borrelia burgdorferi*, *Helicobacter pylori*, *Archaeoglobus fulgidus*, *Methanobacterium thermo.*, *Escherichia coli*, *Mycoplasma pneumoniae*, *Synechocystis* sp., *Methanococcus jannaschii*, *Saccharomyces cerevisiae*, *Mycoplasma genitalium*, *Haemophilus influenzae*, *Rickettsia prowazekii*, *Pyrococcus abyssi*, *Bacillus* sp., *Pseudomonas aeruginosa*, *Ureaplasma urealyticum*, *Pyrobaculum aerophilum*, *Pyrococcus furiosus*, *Mycobacterium tuberculosis*, *Mycobacterium tuberculosis*, *Neisseria gonorrhea*, *Neisseria meningitidis*, *Streptococcus pyogenes*, *Borrelia burgdorferi*, *Caulobacter crescentus*, *Chlorobium tepidum*, *Deinococcus radiodurans*, *Enterococcus faecalis*, *Legionella pneumophila*, *Mycobacterium avium*, *Mycobacterium tuberculosis*, *Methanococcus jannaschii*, *Neisseria meningitidis*, *Pseudomonas putida*, *Porphyromonas gingivalis*, *Salmonella typhimurium*, *Shewanella putrefaciens*, *Streptococcus pneumoniae*, *Vibrio cholerae*, *Clostridium acetobutylicum*, *Campylobacter jejuni*, *Halobacterium salinarum* Institute, *Listeria monocytogenes*, *Mycobacterium tuberculosis* Sanger, *Mycoplasma mycoides*, *Neisseria meningitidis* strain,

Streptomyces coelicolor, Actinobacillus actinomyce, Chlamydia trachomatis, Halobacterium sp., Mycoplasma capricolum, Neisseria gonorrhea, Pseudomonas aeruginosa, Aspergillus nidulans, Candida albicans, Leishmania major, Neurospora crassa, Pneumocystis carinii, Plasmodium falciparum, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Trypanosoma cruzi, 5 Trypanosoma brucei, Abelson murine leukemia virus, Adeno-associated virus 2 or -3, Dengue virus type 1, 2 or 3, Hepatitis A-G virus, Hepatitis GB virus B, Human T-cell lymphotropic virus type 1 or 2, Human T-cell lymphotropic virus type I, Human adenovirus type 12 or 2, Human herpesvirus 1-4, Human immunodeficiency virus type 1-2, Human parainfluenza virus 3, Human respiratory syncytial virus, Infectious hematopoietic necrosis virus, Influenza A virus, Influenza B 10 virus, Influenza C virus and Measles virus. Additional examples of species that produce the targets tested using the methods of the invention are described below.

In a preferred embodiment, the target, e.g., a protein, is produced by a eukaryotic organism, e.g., a single-celled or a multicellular organism. Examples of such eukaryotic organisms include: 15 Arabidopsis thaliana M, Brugia malayi, Caenorhabditis elegans, Drosophila melanogaster, Shistosoma mansoni, Shistosoma japonicum, and mammals, e.g., humans. Preferably, the target is produced by a human.

In a preferred embodiment, the target, e.g., a protein, is produced by an organelle, e.g., the 20 mitochondria, of an organism.

In a preferred embodiment, the target, e.g., the protein, has no known activity (e.g., enzymatic activity), or has an activity which is difficult to measure. In preferred embodiments, the protein has a known first activity and it is tested against a library which includes an interactor 25 which interacts with the protein by way of a second activity, e.g., an unknown activity.

In a preferred embodiment, the target is a naturally occurring protein or fragment thereof; a protein of unknown function and/or structure; a protein for which the ligand, substrate, or other interacting molecule is not known. In other embodiments, the protein has at least one enzymatic 30 activity.

In a preferred embodiment, the target is a nucleic acid, e.g., a DNA or RNA (e.g., structured RNA, e.g., a ribozyme).

In a preferred embodiment, a plurality of library members is tested simultaneously, e.g., in the same reaction mixture, which can allow for an increase in the throughput of the method. A plurality of library members, e.g., one which provides a positive result, can be subdivided into smaller groups and those smaller groups tested. One or more library members from the plurality or from a smaller group, e.g., one which provides a positive result, can be tested individually.

In a preferred embodiment, the method further includes repeating one or more steps, e.g., one or both of steps (4) and (5), under a different condition, e.g., at a different salt concentration, different pH, or in the presence of a different cofactor.

In a preferred embodiment, the method further includes repeating at least one step, e.g., steps (3)-(6) with a second or subsequent member or members of the library. In a preferred embodiment, a plurality of library members, e.g., candidate substrates or test ligands, is tested. In a preferred embodiment, the plurality of library members includes at least 10 , 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , or 10^8 compounds. In a preferred embodiment includes at least 10 , 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , or 10^8 of the library members share a structural or functional characteristic.

In a preferred embodiment, the library includes a plurality of members having a common characteristic, e.g., all members of the plurality are enzyme cofactors; substrates for, e.g., biosynthetic or degradative enzymes (e.g., protease substrates), including carbohydrates, nucleoside/nucleotides, amino acids, lipids; vitamins; hormones; nucleic acids; e.g., DNA molecules; or natural products, e.g., bacterial natural products. The library can include any metabolite, precursor, or intermediate of the members listed above.

In a preferred embodiment, the library is: a substrate library; a cofactor library; a carbohydrate biosynthesis and/or degradation library; a purine and pyrimidine biosynthesis and/or degradation library; an amino acid biosynthesis and/or degradation library; a lipid biosynthesis

and/or degradation library; a vitamin and/or hormone library; a nucleic acid, e.g., DNA, library; or a natural product library, e.g., a bacterial natural product library.

5 In a preferred embodiment, a library member (a potential or candidate interactor) is a species which has potential to interact with a target, e.g., a target protein. Preferably, a library member is a candidate substrate or a test ligand.

10 In a preferred embodiment, a library member is selected from the group consisting of: an enzyme substrate, a metabolite, a cofactor, a natural product (e.g., a bacterial natural product), a carbohydrate, a polysaccharide, a nucleic acid (e.g., a nucleoside or nucleotide precursor, a double-stranded (ds) or single-stranded (ss) DNA molecule, a circular nucleic acid, a super-coiled nucleic acid), an amino acid, (e.g., a D- or L-amino acid or a precursor thereof), a vitamin, a hormone, a lipid, a small organic molecule, a metals, a peptide, a protein, a lipid, a glycoprotein, a glycolipid, a transition state analog and combinations thereof.

15 In a preferred embodiment, the method further includes testing the protein against at least one member of a second library.

20 In a preferred embodiment, two, or more, libraries are tested simultaneously. By way of example, the target can be tested against each (or some) members of a first library, e.g., a cofactor library, and each (or some) members of a second library, e.g., a library of potential substrates. Thus, in the case of two libraries with a first library having 50 members (first₁, first₂, ... first₅₀) and a second library having 50 members (second₁, second₂, ... second₅₀....) the target is tested against all or a plurality of the novel combinations, e.g., against (first₁, second₁), (first₁ second₂) ... (first₁, second₅₀), and so on.

In a preferred embodiment, a library member is a member of a combinatorial library.

30 In a preferred embodiment, the target interacts with, e.g., binds, and preferably modifies, the test compound. Modify, as used herein, includes making or breaking a bond, e.g., a non-covalent or covalent bond, in the test compound or the target. Modification includes cleavage,

degradation, hydrolysis, a change in the level of phosphorylation labeling, ligation, synthesis, and similar reactions. Modification can include changes in activity, e.g., enzymatic activity, physical changes in phase, changes in aggregation, or polymerization.

5 In a preferred embodiment, the method further includes:

analyzing the target structure or function, e.g., analyzing the physical properties of the target; analyzing the target *in vitro* or *in vivo* activity; analyzing the target sequence (e.g., amino acid or nucleotide sequence) for the presence of, e.g., conserved amino acid domains, thereby predicting the target structure or function. In a preferred embodiment, the analysis of the target
10 structure or function is performed prior to contacting the target with the library.

In a preferred embodiment, the method further includes:

selecting a library member, e.g., candidate substrate or test ligand based on its interaction with the target; and confirming that the candidate substrate or test ligand is a substrate or a ligand,
15 respectively.

In a preferred embodiment, the method further includes:

selecting a library member based on its interaction with the target; and contacting the library member with a cell, e.g., a cultured cell, or an animal, and, optionally, determining if the
20 library member has an effect on the cell or animal.

In a preferred embodiment, the method further includes selecting an interactor (e.g., a library member) on the basis of its interaction with the target and: purifying the library, e.g., a candidate substrate or test ligand; crystallizing a library member, e.g., a candidate substrate or test
25 ligand; evaluating a physical property of a library member, e.g., a candidate substrate or test ligand, e.g., molecular weight, isoelectric point, sequence (where relevant), or crystal structure. The library member can be crystallized by itself, or as complexed with the target.

In a preferred embodiment, the method further includes using a library member selected for
30 interacting with the target to identify, e.g., by binding to or interacting with the selected library

member, an agent which modulates an interaction between the target and the selected library member.

In a preferred embodiment, the method further includes selecting an interactor (e.g., a library member) on the basis of its interaction with the target and: optimizing a property of a chosen library member, e.g., candidate substrate or test ligand, e.g., optimizing affinity for the target, altering molecular weight, e.g., decreasing molecular weight, or altering, e.g., increasing, solubility. Optimization can be performed using known methods or methods disclosed herein.

In a preferred embodiment, the change in heat output is measured with a microcalorimeter.

In a preferred embodiment, the method further includes determining a physical constant of an interaction between the protein and a member of the library, e.g., k_{cat} , K_M , or k_D .

In a preferred embodiment, the method can include the use of a linking reaction, e.g., a surrogate ligand, as described elsewhere herein.

In another aspect, the invention features, a method of purifying or isolating an interactor (or a target) from a mixture. (Although in the embodiment described below, an interactor, e.g. a substrate or counter ligand, is purified or isolated using the target as an assay reagent analogous methods, which isolate or purify a target using an interactor, e.g., a substrate, as an assay reagent are also within the invention.) The interactor can be, e.g., a ligand, receptor, counter ligand, cofactor, or substrate, which interacts with a target, e.g., a protein. The mixture can be a complex biological sample, e.g., whole cells, a cell homogenate or lysate, a tissue sample, a sample of a biological fluid. (Although the method is described with regard to a protein, other molecules (referred to herein as a target, e.g., other macromolecules, e.g., nucleic acids, can be analyzed with the methods described herein.) The method includes:

- (1) providing a mixture;
- (2) partitioning the mixture into to a plurality of fractions including a first and a second fraction, e.g., a soluble and a membrane fraction:

- (3) contacting the target with the first fraction to form a first reaction mixture;
 - (4) evaluating a change in heat output of the first reaction mixture;
 - (5) optionally, comparing the value for heat change obtained with a predetermined value;
 - 5 (6) contacting the target with the second fraction to form a second reaction mixture;
 - (7) evaluating a change in heat output of the second reaction mixture;
 - (8) optionally, comparing the value for heat change obtained with a predetermined value;
 - (9) evaluating, e.g., by comparing, the change in heat in the first reaction and the
 - 10 change in heat in the second reaction, and selecting a fraction,
- to thereby purify or isolate the interactor. e.g., a ligand or substrate of a target, e.g., a protein target.

In a preferred embodiment, the target, e.g., a protein, is produced by a pathogen, e.g., a prokaryotic or a eukaryotic pathogen, including a bacterium, a protozoan, a virus, e.g., phage, or a

15 fungus. For example, the protein can be a protein produced by any of the following species: *Aquifex aeolicus*, *Pyrococcus horikoshii*, *Bacillus subtilis*, *Treponema pallidum*, *Borrelia burgdorferi*, *Helicobacter pylori*, *Archaeoglobus fulgidus*, *Methanobacterium thermo.*, *Escherichia coli*, *Mycoplasma pneumoniae*, *Synechocystis sp.*, *Methanococcus jannaschii*, *Saccharomyces cerevisiae*, *Mycoplasma genitalium*, *Haemophilus influenzae*, *Rickettsia prowazekii*, *Pyrococcus*

20 *abyssii*, *Bacillus sp.*, *Pseudomonas aeruginosa*, *Ureaplasma urealyticum*, *Pyrobaculum aerophilum*, *Pyrococcus furiosus*, *Mycobacterium tuberculosis*, *Mycobacterium tuberculosis*, *Neisseria gonorrhea*, *Neisseria meningitidis*, *Streptococcus pyogenes*, *Borrelia burgdorferi*, *Caulobacter crescentus*, *Chlorobium tepidum*, *Deinococcus radiodurans*, *Enterococcus faecalis*, *Legionella pneumophila*, *Mycobacterium avium*, *Mycobacterium tuberculosis*, *Methanococcus jannaschii*,

25 *Neisseria meningitidis*, *Pseudomonas putida*, *Porphyromonas gingivalis*, *Salmonella typhimurium*, *Shewanella putrefaciens*, *Streptococcus pneumoniae*, *Vibrio cholerae*, *Clostridium acetobutylicum*, *Campylobacter jejuni*, *Halobacterium salinarum* Institute, *Listeria monocytogenes*, *Mycobacterium tuberculosis* Sanger, *Mycoplasma mycoides*, *Neisseria meningitidis* strain, *Streptomyces coelicolor*, *Actinobacillus actinomyces*, *Chlamydia trachomatis*, *Halobacterium sp.*,

30 *Mycoplasma capricolum*, *Neisseria gonorrhea*, *Pseudomonas aeruginosa*, *Aspergillus nidulans*, *Candida albicans*, *Leishmania major*, *Neurospora crassa*, *Pneumocystis carinii*, *Plasmodium*

falciparum, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Trypanosoma cruzi*, *Trypanosoma brucei*, Abelson murine leukemia virus, Adeno-associated virus 2 or -3, Dengue virus type 1, 2 or 3, Hepatitis A-G virus, Hepatitis GB virus B, Human T-cell lymphotropic virus type 1 or 2, Human T-cell lymphotropic virus type I, Human adenovirus type 12 or 2, Human
5 herpesvirus 1-4, Human immunodeficiency virus type 1-2, Human parainfluenza virus 3, Human respiratory syncytial virus, Infectious hematopoietic necrosis virus, Influenza A virus, Influenza B virus, Influenza C virus and Measles virus. Additional examples of species that produce the targets tested using the methods of the invention are described below.

10 In a preferred embodiment, the target, e.g., a protein, is produced by a eukaryotic organism, e.g., a single-celled or a multicellular organism. Examples of such eukaryotic organisms include: *Arabidopsis thaliana* M, *Brugia malayi*, *Caenorhabditis elegans*, *Drosophila melanogaster*, *Shistosoma mansoni*, *Shistosoma japonicum*, and mammals, e.g., humans. Preferably, the target is produced by a human.

15 In a preferred embodiment, the target, e.g., a protein, is produced by an organelle, e.g., the mitochondria, of an organism.

20 In a preferred embodiment, the target, e.g., a protein, has no known activity (e.g., enzymatic activity), or has an activity which is difficult to measure.

25 In a preferred embodiment, the target, e.g., a protein, is a naturally-occurring protein or fragment thereof; a protein of unknown function and/or structure; a protein for which the ligand, substrate, or other interacting molecule is not known. In other embodiments, the target, e.g., a protein, has at least one enzymatic activity.

In a preferred embodiment, the target is a nucleic acid, e.g., a DNA or RNA (e.g., structured RNA, e.g., a ribozyme).

In a preferred embodiment, the method further includes repeating one or more steps, e.g., one or both of steps (4) and (5), under a different condition, e.g., at a different salt concentration, different pH, or in the presence of an exogenous cofactor.

5 In a preferred embodiment, the target interacts with, e.g., binds, and preferably modifies, the interactor. Modify, as used herein, includes making or breaking a bond, e.g., a non-covalent or covalent bond, in the test compound or the target. Modification includes cleavage, degradation, hydrolysis, a change in the level of phosphorylation labeling, ligation, synthesis, and similar reactions. Modification can include changes in activity, e.g., enzymatic activity, physical changes
10 in phase, changes in aggregation, or polymerization.

In a preferred embodiment, the method further includes:
analyzing the interactor structure or function, e.g., analyzing the physical properties of the interactor.

15 In a preferred embodiment, the method further includes:
selecting a interactor, e.g., based on its interaction with the target; and confirming that the interactor is, e.g., a substrate or a ligand.

20 In a preferred embodiment, the method further includes:
contacting the purified or isolated interactor with a cell, e.g., a cultured cell, or an animal, and, optionally, determining if purified or isolated interactor has an effect on the cell or animal.

In a preferred embodiment, the method further includes selecting an interactor (e.g., a
25 library member) on the basis of its interaction with the target and: purifying the purified or isolated interactor; crystallizing purified or isolated interactor; evaluating a physical property of the purified or isolated interactor.

In a preferred embodiment, the method further: optimizing a property of a purified or
30 isolated interactor, e.g., optimizing affinity for the target, altering molecular weight, e.g.,

decreasing molecular weight, or altering, e.g., increasing, solubility. Optimization can be performed using known methods or methods disclosed herein.

In a preferred embodiment, the change in heat output is measured with a microcalorimeter.

In a preferred embodiment, the method further includes determining a physical constant of an interaction between the target and purified or isolated interactor, e.g., k_{cat} , K_M , or k_D .

In a preferred embodiment, the method can include the use of a linking reaction, e.g., a surrogate ligand, as described elsewhere herein.

In another aspect, the invention features, a method of analyzing a target, e.g., discovering an interactor, e.g., a substrate or a ligand of a protein. The method includes:

- (a) providing a reaction mixture which includes a target;
- (b) contacting the target with a candidate interactor, e.g., a candidate substrate or a test ligand;
- (c) evaluating a change in heat of the reaction mixture;
- (d) optionally, comparing the value for heat change obtained with a predetermined value, thereby analyzing a target, e.g., discovering a substrate of the target. Although much of the discussion below is directed to proteins and their interactors, e.g., substrates or counter-ligands, it will be understood that the method can be applied to other targets and to other interactors.

In a preferred embodiment, the interactor, e.g., the substrate or ligand, is identified by a change in the heat of the reaction mixture, e.g., change which is greater than a predetermined value.

In a preferred embodiment, a plurality, e.g., a library, of candidate interactors, e.g., candidate substrates or test ligands, is tested. In a preferred embodiment the plurality, e.g., a library, of candidate substrates or test ligands includes at least 10, 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , or 10^8 candidate substrates or test ligands. Thus, in a preferred embodiment method includes:

(a) providing a reaction mixture which includes a first interactor of the plurality and the target;

(b) allowing the first interactor and the target molecule to interact;

(c) measuring a change in heat in the reaction mixture; and,

(d) optionally performing steps (a), (b), and (c) for each remaining interactor of the plurality,

thereby testing a plurality of interactors to determine one or more of the plurality interacts with the target.

In a preferred embodiment, the target, e.g., a protein, is produced by a pathogen, e.g., a prokaryotic or a eukaryotic pathogen, including a bacterium, a protozoan, a virus, e.g., phage, or a fungus. For example, the protein can be a protein produced by any of the following species: *Aquifex aeolicus*, *Pyrococcus horikoshii*, *Bacillus subtilis*, *Treponema pallidum*, *Borrelia burgdorferi*, *Helicobacter pylori*, *Archaeoglobus fulgidus*, *Methanobacterium thermo.*, *Escherichia coli*, *Mycoplasma pneumoniae*, *Synechocystis sp.*, *Methanococcus jannaschii*, *Saccharomyces cerevisiae*, *Mycoplasma genitalium*, *Haemophilus influenzae*, *Rickettsia prowazekii*, *Pyrococcus abyssi*, *Bacillus sp.*, *Pseudomonas aeruginosa*, *Ureaplasma urealyticum*, *Pyrobaculum aerophilum*, *Pyrococcus furiosus*, *Mycobacterium tuberculosis*, *Neisseria gonorrhea*, *Neisseria meningitidis*, *Streptococcus pyogenes*, *Borrelia burgdorferi*, *Caulobacter crescentus*, *Chlorobium tepidum*, *Deinococcus radiodurans*, *Enterococcus faecalis*, *Legionella pneumophila*, *Mycobacterium avium*, *Mycobacterium tuberculosis*, *Methanococcus jannaschii*, *Neisseria meningitidis*, *Pseudomonas putida*, *Porphyromonas gingivalis*, *Salmonella typhimurium*, *Shewanella putrefaciens*, *Streptococcus pneumoniae*, *Vibrio cholerae*, *Clostridium acetobutylicum*, *Campylobacter jejuni*, *Halobacterium salinarum* Institute, *Listeria monocytogenes*, *Mycobacterium tuberculosis* Sanger, *Mycoplasma mycoides*, *Neisseria meningitidis* strain, *Streptomyces coelicolor*, *Actinobacillus actinomyces*, *Chlamydia trachomatis*, *Halobacterium sp.*, *Mycoplasma capricolum*, *Neisseria gonorrhea*, *Pseudomonas aeruginosa*, *Aspergillus nidulans*, *Candida albicans*, *Leishmania major*, *Neurospora crassa*, *Pneumocystis carinii*, *Plasmodium falciparum*, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Trypanosoma cruzi*, *Trypanosoma brucei*, Abelson murine leukemia virus, Adeno-associated virus 2 or -3, Dengue virus type 1, 2 or 3, Hepatitis A-G virus, Hepatitis GB virus B, Human T-cell lymphotropic virus

type 1 or 2, Human T-cell lymphotropic virus type I, Human adenovirus type 12 or 2, Human herpesvirus 1-4, Human immunodeficiency virus type 1-2, Human parainfluenza virus 3, Human respiratory syncytial virus, Infectious hematopoietic necrosis virus, Influenza A virus, Influenza B virus, Influenza C virus and Measles virus. Additional examples of species that produce the targets
5 tested using the methods of the invention are described below.

In a preferred embodiment, the target, e.g., a protein, is produced by a eukaryotic organism, e.g., a single-celled or a multicellular organism. Examples of such eukaryotic organisms include: Arabidopsis thaliana M, Brugia malayi, Caenorhabditis elegans, Drosophila melanogaster,
10 Shistosoma mansoni, Shistosoma japonicum, and mammals, e.g., humans. Preferably, the target is produced by a human.

In a preferred embodiment, the target, e.g., a protein, is produced by an organelle, e.g., the mitochondria, of an organism.
15

In a preferred embodiment, the target has no known activity (e.g., enzymatic activity), or has an activity which is difficult to measure. In preferred embodiments, the target has a known first activity and it is tested against a library which includes an interactor which interacts with the target by way of a second activity, e.g., an unknown activity.
20

In a preferred embodiment, the target is a naturally-occurring protein or fragment thereof; a protein of unknown function and/or structure; a protein for which the ligand, substrate, or other interacting molecule is not known. In other embodiments, the target, e.g., a protein, has at least one enzymatic activity.
25

In a preferred embodiment, the target is a nucleic acid, e.g., a DNA or RNA (e.g., structured RNA, e.g., a ribozyme).

In a preferred embodiment, a plurality of candidate interactors, e.g., library members, is
30 tested simultaneously, e.g., in the same reaction mixture, which can allow for an increase in the throughput of the method. A plurality of library members, e.g., one which provides a positive

result, can be subdivided into smaller groups and those smaller groups tested. One or more library members from the plurality or from a smaller group, e.g., one which provides a positive result, can be tested individually.

5 In a preferred embodiment, the method further includes repeating one or more under a different condition, e.g., at a different salt concentration, different pH, or in the presence of a different cofactor.

10 In a preferred embodiment, the method further includes repeating at least one step with a second or subsequent member or members of the library of candidate interactors. In a preferred embodiment, a plurality of candidate interactors, e.g., library members, is tested. In a preferred embodiment, the plurality of candidate interactors, e.g., library members, includes at least 10 , 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , or 10^8 compounds. In a preferred embodiment includes at least 10 , 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , or 10^8 of the library members share a structural or functional characteristic.

15 In a preferred embodiment, the library of candidate interactors includes a plurality of members having a common characteristic, e.g., all members of the plurality are enzyme cofactors; substrates for, e.g., biosynthetic or degradative enzymes (e.g., protease substrates), including carbohydrates, nucleoside/nucleotides, amino acids, lipids; vitamins; hormones; nucleic acids; e.g.,
20 DNA molecules; or natural products, e.g., bacterial natural products. The library can include any metabolite, precursor, or intermediate of the members listed above.

In a preferred embodiment, the library of candidate interactors is: a substrate library; a cofactor library; a carbohydrate biosynthesis and/or degradation library; a purine and pyrimidine
25 biosynthesis and/or degradation library; an amino acid biosynthesis and/or degradation library; a lipid biosynthesis and/or degradation library; a vitamin and/or hormone library; a nucleic acid, e.g., DNA library; or a natural product library, e.g., a bacterial natural product library.

30 In a preferred embodiment, the candidate interactor is a species which has potential to interact with a target, e.g., a target protein. Preferably, the candidate interactor is a candidate substrate or a test ligand.

In a preferred embodiment, the candidate interactor is selected from the group consisting of: an enzyme substrate, a metabolite, a cofactor, a natural product (e.g., a bacterial natural product), a carbohydrate, a polysaccharide, a nucleic acid, (e.g., a nucleoside or nucleotide precursor, a ds or ss
5 DNA molecule, a circular nucleic acid, a super-coiled nucleic acid), an amino acid, (e.g., a D- or L-amino acid or a precursor thereof), a vitamin, a hormone, a lipid, a small organic molecule, a metals, a peptide, a protein, a lipid, a glycoprotein, a glycolipid, a transition state analog and combinations thereof.

10 In a preferred embodiment, the method further includes testing the candidate interactor against at least one member of a second library.

In a preferred embodiment, two, or more, libraries of candidate interactors are tested simultaneously. By way of example, the target can be tested against each (or some) members of a
15 first library, e.g., a cofactor library, and each (or some) members of a second library, e.g., a library of potential substrates. Thus, in the case of two libraries with a first library having 50 members ($first_1, first_2, \dots first_{50}$) and a second library having 50 members ($second_1, second_2, \dots second_{50}$) the target is tested against all or a plurality of the novel combinations, e.g., against ($first_1, second_1$), ($first_1, second_2$) ... ($first_1, second_{50}$), and so on.

20 In a preferred embodiment, the member of the library of candidate interactors is a member of a combinatorial library.

In a preferred embodiment, the target interacts with, e.g., binds to, and preferably modifies,
25 the candidate interactor. Modify, as used herein, includes making or breaking a bond, e.g., a non-covalent or covalent bond, in the candidate interactor or the target. Modification includes cleavage, degradation, hydrolysis, a change in the level of phosphorylation labeling, ligation, synthesis, and similar reactions. Modification can include changes in activity, e.g., enzymatic activity, physical changes in phase, changes in aggregation, or polymerization.

30 In a preferred embodiment, the method further includes:

analyzing the target structure or function, e.g., analyzing the physical properties of the target; analyzing the target *in vitro* or *in vivo* activity; analyzing the target sequence (e.g., amino acid or nucleotide sequence) for the presence of, e.g., conserved amino acid domains, thereby predicting the target structure or function. In a preferred embodiment, the analysis of the target structure or function is performed prior to contacting the target with the candidate interactor.

In a preferred embodiment, the method further includes:

selecting a candidate interactor, e.g., a library member, based on its interaction with the target; and confirming that the candidate interactor interacts with the target, e.g., is a substrate or a ligand of the target, respectively.

In a preferred embodiment, the method further includes:

selecting a candidate interactor, e.g., library member, based on its interaction with the target; and contacting the library member with a cell, e.g., a cultured cell, or an animal, and, optionally, determining if the library member has an effect on the cell or animal.

In a preferred embodiment, the method further includes selecting a candidate interactor (e.g., a library member) on the basis of its interaction with the target and: purifying the library, e.g., a candidate substrate or test ligand; crystallizing a library member, e.g., a candidate substrate or test ligand; evaluating a physical property of a library member, e.g., a candidate substrate or test ligand, e.g., molecular weight, isoelectric point, sequence (where relevant), or crystal structure.

In a preferred embodiment, the method further includes using a library member selected for interacting with the target to identify, e.g., by binding to or interacting with the selected library member, an agent which modulates an interaction between the target and the selected library member.

In a preferred embodiment, the method further includes selecting a candidate interactor (e.g., a library member) on the basis of its interaction with the target and: optimizing a property of a chosen library member, e.g., candidate substrate or test ligand, e.g., optimizing affinity for the

target, altering molecular weight, e.g., decreasing molecular weight, or altering, e.g., increasing, solubility. Optimization can be performed using known methods or methods disclosed herein.

In a preferred embodiment, the change in heat output is measured with a microcalorimeter.

In a preferred embodiment, the method further includes determining a physical constant of an interaction between the protein and a member of the library, e.g., k_{cat} , K_M , or k_D .

In a preferred embodiment, the method can include the use of a linking reaction, e.g., a surrogate ligand, as described elsewhere herein.

Embodiments of the method can include the use of a linking interaction, e.g., a surrogate ligand, as is described herein. Thus, in a preferred embodiment one or more steps, e.g., step (b), further includes the inclusion of a surrogate ligand and a signal-generating entity, and the interaction of the surrogate ligand, e.g., displaced surrogate ligand, and the signal-generating entity, as described elsewhere herein.

In another aspect, the invention features, a method of modifying, e.g., optimizing, the structure of a compound. The parameter optimized can be, e.g., the ability of the compound to interact with a target, e.g., for the ability to bind or modify the target. The method includes:

- (a) providing a target;
- (b) modifying the structure of a test compound, e.g., by a process which involves making or breaking a bond, e.g., a covalent or non-covalent bond, to provide a modified compound
- (c) contacting the target molecule with the modified compound to provide a reaction mixture;
- (d) evaluating the change in heat associated with the reaction mixture;
- (e) optionally, comparing the value determined in (d) with a predetermined value, thereby providing a modified compound.

In a preferred embodiment, the method includes:

- (a) providing a target;
- (b) contacting the target molecule with a test compound to provide a reaction mixture;
- (c) determining the change in heat associated with the reaction mixture;
- (d) optionally, comparing the value determined in (c) with a predetermined value, and if the

5 value and the predetermined value manifest a predetermined relationship, e.g., if the former is equal to or less than the latter, then

(e) modifying the structure of the test compound, e.g., by making or breaking a bond, e.g., a covalent or non-covalent bond, to provide a compound.

thereby providing a compound with a modified. In a preferred embodiment the method can further
10 include one or more cycles of the following steps:

(f) contacting the target molecule with the modified test compound to provide a reaction mixture;

(g) determining the change in heat associated with the reaction mixture;

(h) optionally, comparing the value determined in (g) with a predetermined value, and if the
15 value and the predetermined value manifest a predetermined relationship, e.g., if the former is equal to or less than the latter, then

(i) modifying the structure of the modified test compound, e.g., by making or breaking a bond, e.g., a covalent or non-covalent bond, to provide a compound.

20 In a preferred embodiment, the target, e.g., a protein, is produced by a pathogen, e.g., a prokaryotic or a eukaryotic pathogen, including a bacterium, a protozoan, a virus, e.g., phage, or a fungus. For example, the protein can be a protein produced by any of the following species: *Aquifex aeolicus*, *Pyrococcus horikoshii*, *Bacillus subtilis*, *Treponema pallidum*, *Borrelia burgdorferi*, *Helicobacter pylori*, *Archaeoglobus fulgidus*, *Methanobacterium thermo.*, *Escherichia coli*, *Mycoplasma pneumoniae*, *Synechocystis sp.*, *Methanococcus jannaschii*, *Saccharomyces cerevisiae*, *Mycoplasma genitalium*, *Haemophilus influenzae*, *Rickettsia prowazekii*, *Pyrococcus abyssi*, *Bacillus sp.*, *Pseudomonas aeruginosa*, *Ureaplasma urealyticum*, *Pyrobaculum aerophilum*, *Pyrococcus furiosus*, *Mycobacterium tuberculosis*, *Mycobacterium tuberculosis*, *Neisseria gonorrhea*, *Neisseria meningitidis*, *Streptococcus pyogenes*, *Borellia burgdorferi*, *Caulobacter*
25 *crescentus*, *Chlorobium tepidum*, *Deinococcus radiodurans*, *Enterococcus faecalis*, *Legionella pneumophila*, *Mycobacterium avium*, *Mycobacterium tuberculosis*, *Methanococcus jannaschii*,

Neisseria meningitides, Pseudomonas putida, Porphyromonas gingivalis, Salmonella typhimurium, Shewanella putrefaciens, Streptococcus pneumoniae, Vibrio cholerae, Clostridium acetobutylicum, Campylobacter jejuni, Halobacterium salinarum Institute, Listeria monocytogenes, Mycobacterium tuberculosis Sanger, Mycoplasma mycoides, Neisseria meningitidis strain,

5 Streptomyces coelicolor, Actinobacillus actinomyces, Chlamydia trachomatis, Halobacterium sp., Mycoplasma capricolum, Neisseria gonorrhea, Pseudomonas aeruginosa, Aspergillus nidulans, Candida albicans, Leishmania major, Neurospora crassa, Pneumocystis carinii, Plasmodium falciparum, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Trypanosoma cruzi, Trypanosoma brucei, Abelson murine leukemia virus, Adeno-associated virus 2 or -3, Dengue

10 virus type 1, 2 or 3, Hepatitis A-G virus, Hepatitis GB virus B, Human T-cell lymphotropic virus type 1 or 2, Human T-cell lymphotropic virus type I, Human adenovirus type 12 or 2, Human herpesvirus 1-4, Human immunodeficiency virus type 1-2, Human parainfluenza virus 3, Human respiratory syncytial virus, Infectious hematopoietic necrosis virus, Influenza A virus, Influenza B virus, Influenza C virus and Measles virus. Additional examples of species that produce the targets

15 tested using the methods of the invention are described below.

In a preferred embodiment, the target, e.g., a protein, is produced by a eukaryotic organism, e.g., a single-celled or a multicellular organism. Examples of such eukaryotic organisms include: Arabidopsis thaliana M, Brugia malayi, Caenorhabditis elegans, Drosophila melanogaster,

20 Shistosoma mansoni, Shistosoma japonicum, and mammals, e.g., humans. Preferably, the target is produced by a human.

In a preferred embodiment, the target, e.g., a protein, is produced by an organelle, e.g., the mitochondria, of an organism.

25

In a preferred embodiment, the target, e.g., protein has no known activity (e.g., enzymatic activity), or has an activity which is difficult to measure. In preferred embodiments, the target, e.g., a protein, has a known first activity and it is tested against a library which includes an interactor which interacts with the protein by way of a second activity, e.g., an unknown activity.

30

In a preferred embodiment, the target is a naturally-occurring protein or fragment thereof; a protein of unknown function and/or structure; a protein for which the ligand, substrate, or other interacting molecule is not known. In other embodiments, the target, e.g., a protein, has at least one enzymatic activity.

5

In a preferred embodiment, the target is a nucleic acid, e.g., a DNA or RNA (e.g., structured RNA, e.g., a ribozyme).

10

In a preferred embodiment, the test compound (a potential or candidate interactor) is a species which has potential to interact with a target, e.g., a target protein. Preferably, the test compound is a candidate substrate or a test ligand.

15

In a preferred embodiment, the test compound is a member of a library that includes a plurality of members having a common characteristic, e.g., all members of the plurality are enzyme cofactors; substrates for, e.g., biosynthetic or degradative enzymes (e.g., protease substrates), including carbohydrates, nucleoside/nucleotides, amino acids, lipids; vitamins; hormones; nucleic acids; e.g., DNA molecules; or natural products, e.g., bacterial natural products. The library can include any metabolite, precursor, or intermediate of the members listed above.

20

In a preferred embodiment, the test compound is a member of a library selected from the group consisting of: a substrate library; a cofactor library; a carbohydrate biosynthesis and/or degradation library; a purine and pyrimidine biosynthesis and/or degradation library; an amino acid biosynthesis and/or degradation library; a lipid biosynthesis and/or degradation library; a vitamin and/or hormone library; a nucleic acid, e.g., DNA library; or a natural product library, e.g., a bacterial natural product library.

25

In a preferred embodiment, the test compound is selected from the group consisting of: an enzyme substrate, a metabolite, a cofactor, a natural product (e.g., a bacterial natural product), a carbohydrate, a polysaccharide, a nucleic acid, (e.g., a nucleoside or nucleotide precursor, a ds or ss DNA molecule, a circular nucleic acid, a super-coiled nucleic acid), an amino acid, (e.g., a D- or L-amino acid or a precursor thereof), a vitamin, a hormone, a lipid, a small organic molecule, a

30

metals, a peptide, a protein, a lipid, a glycoprotein, a glycolipid, a transition state analog and combinations thereof.

In a preferred embodiment, a test compound is a member of a combinatorial library.

5

In a preferred embodiment, the target interacts with, e.g., binds, and preferably modifies, the test compound. Modify, as used herein, includes making or breaking a bond, e.g., a non-covalent or covalent bond, in the test compound or the target. Modification includes cleavage, degradation, hydrolysis, a change in the level of phosphorylation labeling, ligation, synthesis, and similar reactions. Modification can include changes in activity, e.g., enzymatic activity, physical changes in phase, changes in aggregation, or polymerization.

10

In a preferred embodiment, the method further includes:

analyzing the test compound, or modified test compound structure or function, e.g., analyzing the physical properties of the the test compound or modified test compound; analyzing the the test compound or modified test compound *in vitro* or *in vivo* activity.

15

In a preferred embodiment, the method further includes:

selecting a test compound or modified test compound, and contacting it with a cell, e.g., a cultured cell, or an animal, and, optionally, determining if the test compound or modified test compound has an effect on the cell or animal.

20

In a preferred embodiment, the method further includes selecting test compound or modified test compound, e.g., on the basis of its interaction with the target and: purifying the test compound or modified test compound; crystallizing test compound or modified test compound; evaluating a physical property of a test compound or modified test compound, e.g., molecular weight, isoelectric point, sequence (where relevant), or crystal structure.

25

In a preferred embodiment, the method further includes purifying the test compound or modified test compound, e.g., on the basis of its interaction with the target and: optimizing a property of test compound or modified test compound, e.g., optimizing affinity for the target,

30

altering molecular weight, e.g., decreasing molecular weight, or altering, e.g., increasing, solubility. Optimization can be performed using known methods or methods disclosed herein.

In a preferred embodiment, the change in heat output is measured with a microcalorimeter.

5

In a preferred embodiment the method further includes determining a physical constant of an interaction between the target and the test compound or modified test compound, e.g., k_{cat} , K_M , or k_D .

10 In a preferred embodiment the method can include the use of a linking reaction, e.g., a surrogate ligand, as described elsewhere herein.

In another aspect, the invention features, a method of comparing two interactors, e.g.,
15 ligands, e.g., an initial ligand structure and a modification thereof. The interactors can be compared, e.g., for the ability to interact with a target, e.g., for the ability to bind or modify the target. The method includes:

- (a) providing a target;
- (b) contacting the target with a first interactor, e.g., a first ligand to provide a reaction
20 mixture;
- (c) determining the change in heat associated with the reaction mixture;
- (d) providing a modified interactor, e.g., modified ligand, i.e., a ligand molecule in which one or more changes have been made;
- (e) contacting the target with a modified interactor, e.g., modified ligand, to provide a
25 reaction mixture;
- (f) determining the change in heat associated with the reaction mixture in (e); and
- (g) comparing the measurements made in (c) and (f),

thereby comparing two interactors or ligands, e.g., an initial structure and a modification thereof.

30

In a preferred embodiment the steps can be performed in any order, e.g., (a-c) on the one hand, can be performed first, and (d-f) on the other hand, subsequently. In another preferred embodiment (a-c) on the one hand, and (d-f) on the other hand, can be performed completely or partly simultaneously.

5

In a preferred embodiment, the target, e.g., a protein, is produced by a pathogen, e.g., a prokaryotic or a eukaryotic pathogen, including a bacterium, a protozoan, a virus, e.g., phage, or a fungus. For example, the protein can be a protein produced by any of the following species:

Aquifex aeolicus, Pyrococcus horikoshii, Bacillus subtilis, Treponema pallidum, Borrelia burgdorferi, Helicobacter pylori, Archaeoglobus fulgidus, Methanobacterium thermo., Escherichia coli, Mycoplasma pneumoniae, Synechocystis sp., Methanococcus jannaschii, Saccharomyces cerevisiae, Mycoplasma genitalium, Haemophilus influenzae, Rickettsia prowazekii, Pyrococcus abyssi, Bacillus sp., Pseudomonas aeruginosa, Ureaplasma urealyticum, Pyrobaculum aerophilum, Pyrococcus furiosus, Mycobacterium tuberculosis, Mycobacterium tuberculosis, Neisseria gonorrhea, Neisseria meningitidis, Streptococcus pyogenes, Borrelia burgdorferi, Caulobacter crescentus, Chlorobium tepidum, Deinococcus radiodurans, Enterococcus faecalis, Legionella pneumophila, Mycobacterium avium, Mycobacterium tuberculosis, Methanococcus jannaschii, Neisseria meningitidis, Pseudomonas putida, Porphyromonas gingivalis, Salmonella typhimurium, Shewanella putrefaciens, Streptococcus pneumoniae, Vibrio cholerae, Clostridium acetobutylicum, Campylobacter jejuni, Halobacterium salinarum Institute, Listeria monocytogenes, Mycobacterium tuberculosis Sanger, Mycoplasma mycoides, Neisseria meningitidis strain, Streptomyces coelicolor, Actinobacillus actinomyces, Chlamydia trachomatis, Halobacterium sp., Mycoplasma capricolum, Neisseria gonorrhea, Pseudomonas aeruginosa, Aspergillus nidulans, Candida albicans, Leishmania major, Neurospora crassa, Pneumocystis carinii, Plasmodium falciparum, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Trypanosoma cruzi, Trypanosoma brucei, Abelson murine leukemia virus, Adeno-associated virus 2 or -3, Dengue virus type 1, 2 or 3, Hepatitis A-G virus, Hepatitis GB virus B, Human T-cell lymphotropic virus type 1 or 2, Human T-cell lymphotropic virus type I, Human adenovirus type 12 or 2, Human herpesvirus 1-4, Human immunodeficiency virus type 1-2, Human parainfluenza virus 3, Human respiratory syncytial virus, Infectious hematopoietic necrosis virus, Influenza A virus, Influenza B

virus, Influenza C virus and Measles virus. Additional examples of species that produce the targets tested using the methods of the invention are described below.

In a preferred embodiment, the target, e.g., a protein, is produced by a eukaryotic organism, e.g., a single-celled or a multicellular organism. Examples of such eukaryotic organisms include: *Arabidopsis thaliana* M, *Brugia malayi*, *Caenorhabditis elegans*, *Drosophila melanogaster*, *Shistosoma mansoni*, *Shistosoma japonicum*, and mammals, e.g., humans. Preferably, the target is produced by a human.

In a preferred embodiment, the target, e.g., a protein, is produced by an organelle, e.g., the mitochondria, of an organism.

In a preferred embodiment, the target, e.g., a protein, has no known activity (e.g., enzymatic activity), or has an activity which is difficult to measure.

In a preferred embodiment, the target is a naturally occurring protein or fragment thereof; a protein of unknown function and/or structure; a protein for which the ligand, substrate, or other interacting molecule is not known. In other embodiments, the target e.g., a protein, has at least one enzymatic activity.

In a preferred embodiment, the target is a nucleic acid, e.g., a DNA or RNA (e.g., structured RNA, e.g., a ribozyme).

In a preferred embodiment, the method further includes repeating one or more steps under a different condition, e.g., at a different salt concentration, different pH, or in the presence of a different cofactor.

In a preferred embodiment, the target interacts with, e.g., binds, and preferably modifies, the interactor. Modify, as used herein, includes making or breaking a bond, e.g., a non-covalent or covalent bond, in the test compound or the target. Modification includes cleavage, degradation, hydrolysis, a change in the level of phosphorylation labeling, ligation, synthesis, and similar

reactions. Modification can include changes in activity, e.g., enzymatic activity, physical changes in phase, changes in aggregation, or polymerization.

In a preferred embodiment, the method further includes:

5 analyzing an interactor structure or function, e.g., analyzing the physical properties of an interactor; analyzing an interactor *in vitro* or *in vivo* activity

In a preferred embodiment, the method further includes:

10 selecting an interactor, e.g., based on its interaction with the target; and contacting an interactor with a cell, e.g., a cultured cell, or an animal, and, optionally, determining if interactor has an effect on the cell or animal.

In a preferred embodiment, the method further includes selecting an interactor, e.g., on the basis of its interaction with the target and: an interactor; evaluating a physical
15 property of an interactor, e.g., molecular weight, isoelectric point, sequence (where relevant), or crystal structure.

In a preferred embodiment, the method further includes selecting an interactor on the basis of its interaction with the target and: optimizing a property of the interactor, e.g., optimizing
20 affinity for the target, altering molecular weight, e.g., decreasing molecular weight, or altering, e.g., increasing, solubility. Optimization can be performed using known methods or methods disclosed herein.

25 In a preferred embodiment, the change in heat output is measured with a microcalorimeter.

In a preferred embodiment, the method further includes determining a physical constant of an interaction between the protein and an interactor, e.g., k_{cat} , K_M , or k_D .

30 In a preferred embodiment, the method can include the use of a linking reaction, e.g., a surrogate ligand, as described elsewhere herein.

In another aspect, the invention features, a method of comparing a subject molecule and a modification thereof, e.g., an initial structure and a modification thereof. The method includes:

(a) providing a subject molecule;

5 (b) allowing the subject molecule to undergo an interaction with a second molecule, e.g., binding, with a ligand, or an interaction between a first moiety of the subject molecule and a second moiety of the subject molecule;

(c) determining the change in heat associated with the interaction;

(d) providing a modified subject molecule in which one or more changes have been made;

10 (e) allowing the modified subject molecule to undergo an interaction with a second molecule, e.g., binding, with a ligand, or an interaction between a first moiety of the subject molecule and a second moiety of the subject molecule;

(f) determining the change in heat associated with the interaction in (e); and

(g) comparing (c) and (f),

15 thereby comparing a subject molecule and a modification thereof.

In a preferred embodiment the steps can be performed in any order, e.g., (a-c) on the one hand, can be performed first and (d-f) on the other hand, subsequently or, (a-c) on the one hand, and (d-f) on the other hand, can be performed completely or partly simultaneously.

20 In a preferred embodiment, the method further includes:

selecting a modified molecule which interacts with the target; and confirming that the modified molecule interacts with, e.g., binds, to the target in a second test, e.g., one in which the surrogate ligand is not present.

25 In a preferred embodiment, the method further includes:

selecting a modified molecule which interacts with the target; and confirming that the modified molecule interacts with, e.g., binds, to the target by contacting the modified molecule with the target *in vitro*, e.g., in the absence of the surrogate modified molecule.

30 In a preferred embodiment, the method further includes:

selecting a modified molecule which interacts with the target; and contacting the ligand with a cell, e.g., a cultured cell, or an animal, and, optionally, determining if the ligand has an effect on the cell or animal.

5 In a preferred embodiment the method further includes: purifying a test ligand; crystallizing a test ligand; evaluating a physical property of a test ligand, e.g., molecular weight, isoelectric point, sequence (where relevant), or crystal structure.

10 In a preferred embodiment the method further includes: optimizing a property of a chosen test ligand, e.g., optimizing affinity for the target, altering molecular weight, e.g., decreasing molecular weight, or altering, e.g., increasing, solubility. Optimization can be performed using known methods or methods disclosed herein,

15 In a preferred embodiment the change in heat is measured with a microcalorimeter.

In another aspect, the invention features, a method of analyzing a compound, e.g., a protein or nucleic acid, e.g., a structured RNA, or other target. The method includes:

- (a) providing reaction mixture which includes a target;
 - (b) inducing a conformational change in the target in the absence of an interaction or entity, e.g., the absence of an interaction with a ligand (or other library member), or in the absence of a ligand (or other library member);
 - (c) measuring the change in heat evolved in said conformational change;
 - (d) inducing a conformational change in the target in the presence of an interaction or entity, e.g., the presence of an interaction with a ligand (or other library member) or in the presence of a ligand (or other library member);
 - (e) measuring the change in heat evolved in said conformational change; and
 - (g) comparing the value obtained in (c) with the value obtained in (e),
- thereby analyzing a target.

30 In a preferred embodiment a denaturant, e.g., guanidine hydrochloride, urea, or a similar agent, is added to the reaction mixture.

In a preferred embodiment the measurement is made with a microcalorimeter.

In a preferred embodiment the method includes:

- 5 (a) providing reaction mixture which includes a target;
- (b) adding heat to the reaction mixture in the absence of an interaction or entity, e.g., the absence of an interaction with a ligand or in the absence of a ligand;
- (c) measuring the change in heat evolved in said conformational change, e.g., to obtain an apparent specific heat output;
- 10 (d) adding heat to the reaction mixture in the presence of an interaction or entity, e.g., the presence of an interaction with a ligand or in the presence of a ligand;
- (e) measuring the change in heat evolved in said conformational change, e.g., to obtain an apparent specific heat output; and
- (g) comparing the value obtained in (c) with the value obtained in (e),
- 15 thereby analyzing a target, e.g., to determine the binding of a ligand to the target.

In a preferred embodiment, the target is a protein or polypeptide, a nucleic acid, e.g., an RNA. It can be purified, partially purified, or in a crude state.

- 20 In a preferred embodiment, a denaturant, e.g., guanidine hydrochloride, urea, or a similar agent, is added to the reaction mixture.

- In a preferred embodiment, one or more conditions, e.g., the concentration of the denaturant and the target, or the temperature, is chosen such the presence of a ligand that binds the relatively
25 more compactly folded state results in a relatively large change in heat, e.g., by driving the target molecules into the folded state.

In a preferred embodiment, the change in heat is measured with a microcalorimeter.

- 30 In a preferred embodiment, the target, e.g., a protein, is produced by a pathogen, e.g., a prokaryotic or a eukaryotic pathogen, including a bacterium, a protozoan, a virus, e.g., phage, or a

fungus. For example, the protein can be a protein produced by any of the following species:

Aquifex aeolicus, Pyrococcus horikoshii, Bacillus subtilis, Treponema pallidum, Borrelia burgdorferi, Helicobacter pylori, Archaeoglobus fulgidus, Methanobacterium thermo., Escherichia coli, Mycoplasma pneumoniae, Synechocystis sp., Methanococcus jannaschii, Saccharomyces cerevisiae, Mycoplasma genitalium, Haemophilus influenzae, Rickettsia prowazekii, Pyrococcus abyssii, Bacillus sp., Pseudomonas aeruginosa, Ureaplasma urealyticum, Pyrobaculum aerophilum, Pyrococcus furiosus, Mycobacterium tuberculosis, Mycobacterium tuberculosis, Neisseria gonorrhea, Neisseria meningitidis, Streptococcus pyogenes, Borrelia burgdorferi, Caulobacter crescentus, Chlorobium tepidum, Deinococcus radiodurans, Enterococcus faecalis, Legionella pneumophila, Mycobacterium avium, Mycobacterium tuberculosis, Methanococcus jannaschii, Neisseria meningitidis, Pseudomonas putida, Porphyromonas gingivalis, Salmonella typhimurium, Shewanella putrefaciens, Streptococcus pneumoniae, Vibrio cholerae, Clostridium acetobutylicum, Campylobacter jejuni, Halobacterium salinarum Institute, Listeria monocytogenes, Mycobacterium tuberculosis Sanger, Mycoplasma mycoides, Neisseria meningitidis strain, Streptomyces coelicolor, Actinobacillus actinomyces, Chlamydia trachomatis, Halobacterium sp., Mycoplasma capricolum, Neisseria gonorrhea, Pseudomonas aeruginosa, Aspergillus nidulans, Candida albicans, Leishmania major, Neurospora crassa, Pneumocystis carinii, Plasmodium falciparum, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Trypanosoma cruzi, Trypanosoma brucei, Abelson murine leukemia virus, Adeno-associated virus 2 or -3, Dengue virus type 1, 2 or 3, Hepatitis A-G virus, Hepatitis GB virus B, Human T-cell lymphotropic virus type 1 or 2, Human T-cell lymphotropic virus type I, Human adenovirus type 12 or 2, Human herpesvirus 1-4, Human immunodeficiency virus type 1-2, Human parainfluenza virus 3, Human respiratory syncytial virus, Infectious hematopoietic necrosis virus, Influenza A virus, Influenza B virus, Influenza C virus and Measles virus. Additional examples of species that produce the targets tested using the methods of the invention are described below.

In a preferred embodiment, the target, e.g., a protein, is produced by a eukaryotic organism, e.g., a single-celled or a multicellular organism. Examples of such eukaryotic organisms include: Arabidopsis thaliana M, Brugia malayi, Caenorhabditis elegans, Drosophila melanogaster, Shistosoma mansoni, Shistosoma japonicum, and mammals, e.g., humans. Preferably, the target is produced by a human.

In a preferred embodiment, the target, e.g., a protein, is produced by an organelle, e.g., the mitochondria, of an organism.

5 In a preferred embodiment, the target, e.g., the protein, has no known activity (e.g., enzymatic activity), or has an activity which is difficult to measure. In preferred embodiments, the target, e.g., protein, has a known first activity and it is tested against a library which includes an interactor which interacts with the protein by way of a second activity, e.g., an unknown activity.

10 In a preferred embodiment, the target is a naturally occurring protein or fragment thereof; a protein of unknown function and/or structure; a protein for which the ligand, substrate, or other interacting molecule is not known. In other embodiments, the target, e.g., the protein, has at least one enzymatic activity.

15 In a preferred embodiment, the target is a nucleic acid, e.g., a DNA or RNA (e.g., structured RNA, e.g., a ribozyme).

20 In a preferred embodiment, a plurality of library members is tested simultaneously, e.g., in the same reaction mixture, which can allow for an increase in the throughput of the method. A plurality of library members, e.g., one which provides a positive result, can be subdivided into smaller groups and those smaller groups tested. One or more library members from the plurality or from a smaller group, e.g., one which provides a positive result, can be tested individually.

25 In a preferred embodiment, the method further includes repeating one or more steps under a different condition, e.g., at a different salt concentration, different pH, or in the presence of a different cofactor.

30 In a preferred embodiment, the method further includes repeating at least one with a second or subsequent member or members of the library. In a preferred embodiment, a plurality of library members, e.g., candidate substrates or test ligands, is tested. In a preferred embodiment, the plurality of library members includes at least 10 , 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , or 10^8 compounds. In

a preferred embodiment includes at least 10 , 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , or 10^8 of the library members share a structural or functional characteristic.

In a preferred embodiment, the library includes a plurality of members having a common characteristic, e.g., all members of the plurality are enzyme cofactors; substrates for, e.g., biosynthetic or degradative enzymes (e.g., protease substrates), including carbohydrates, nucleoside/nucleotides, amino acids, lipids; vitamins; hormones; nucleic acids; e.g., DNA molecules; or natural products, e.g., bacterial natural products. The library can include any metabolite, precursor, or intermediate of the members listed above.

In a preferred embodiment, the library is: a substrate library; a cofactor library; a carbohydrate biosynthesis and/or degradation library; a purine and pyrimidine biosynthesis and/or degradation library; an amino acid biosynthesis and/or degradation library; a lipid biosynthesis and/or degradation library; a vitamin and/or hormone library; a nucleic acid, e.g., DNA library; or a natural product library, e.g., a bacterial natural product library.

In a preferred embodiment, a library member (a potential or candidate interactor) is a species which has potential to interact with a target, e.g., a target protein. Preferably, a library member is a candidate substrate or a test ligand.

In a preferred embodiment, a library member is selected from the group consisting of: an enzyme substrate, a metabolite, a cofactor, a natural product (e.g., a bacterial natural product), a carbohydrate, a polysaccharide, a nucleic acid, (e.g., a nucleoside or nucleotide precursor, a ds or ss DNA molecule, a circular nucleic acid, a super-coiled nucleic acid), an amino acid, (e.g., a D- or L-amino acid or a precursor thereof), a vitamin, a hormone, a lipid, a small organic molecule, a metals, a peptide, a protein, a lipid, a glycoprotein, a glycolipid, a transition state analog and combinations thereof.

In a preferred embodiment, the method further includes testing the protein against at least one member of a second library.

In a preferred embodiment, two, or more, libraries are tested simultaneously. By way of example, the target can be tested against each (or some) members of a first library, e.g., a cofactor library, and each (or some) members of a second library, e.g., a library of potential substrates. Thus, in the case of two libraries with a first library having 50 members (first₁, first₂, ... first₅₀) and
5 a second library having 50 members (second₁, second₂, ... second₅₀....) the target is tested against all or a plurality of the novel combinations, e.g., against (first₁, second₁), (first₁ second₂) ... (first₁, second₅₀), and so on.

In a preferred embodiment, a library member is a member of a combinatorial library.

10 In a preferred embodiment, the target interacts with, e.g., binds, and preferably modifies, the library member. Modify, as used herein, includes making or breaking a bond, e.g., a non-covalent or covalent bond, in the test compound or the target. Modification includes cleavage, degradation, hydrolysis, a change in the level of phosphorylation labeling, ligation, synthesis, and
15 similar reactions. Modification can include changes in activity, e.g., enzymatic activity, physical changes in phase, changes in aggregation, or polymerization.

In a preferred embodiment, the method further includes:

analyzing library member structure or function, e.g., analyzing the physical properties of the
20 target; analyzing library member *in vitro* or *in vivo* activity.

In a preferred embodiment, the method further includes:

selecting a library member, e.g., candidate substrate or test ligand based on its interaction with the target; and confirming that the candidate substrate or test ligand is a substrate or a ligand,
25 respectively.

In a preferred embodiment, the method further includes:

selecting a library member based on its interaction with the target; and contacting the library member with a cell, e.g., a cultured cell, or an animal, and, optionally, determining if the
30 library member has an effect on the cell or animal.

In a preferred embodiment, the method further includes selecting an interactor (e.g., a library member) on the basis of its interaction with the target and: purifying the library, e.g., a candidate substrate or test ligand; crystallizing a library member, e.g., a candidate substrate or test ligand; evaluating a physical property of a library member, e.g., a candidate substrate or test ligand, e.g., molecular weight, isoelectric point, sequence (where relevant), or crystal structure.

In a preferred embodiment, the method further includes using a library member selected for interacting with the target to identify, e.g., by binding to or interacting with the selected library member, an agent which modulates an interaction between the target and the selected library member.

In a preferred embodiment, the method further includes selecting an interactor (e.g., a library member) on the basis of its interaction with the target and: optimizing a property of a chosen library member, e.g., candidate substrate or test ligand, e.g., optimizing affinity for the target, altering molecular weight, e.g., decreasing molecular weight, or altering, e.g., increasing, solubility. Optimization can be performed using known methods or methods disclosed herein.

In a preferred embodiment, the change in heat output is measured with a microcalorimeter.

In a preferred embodiment, the method further includes determining a physical constant of an interaction between the protein and a member of the library, e.g., k_{cat} , K_M , or k_D .

In another aspect, the invention features, a method of analyzing an interactor, e.g., a substrate, e.g., discovering a target molecule which modifies the substrate. The method includes: providing a reaction mixture which includes the interactor, e.g., substrate; contacting the interactor with a candidate target; evaluating a change in heat the reaction mixture; optionally, comparing the value for heat change obtained with a predetermined value, thereby of analyzing a interactor, e.g., discovering a target for the interactor.

In a preferred embodiment, the interactor is identified by a change in the heat of the reaction mixture, e.g., change which is greater than a predetermined value.

In a preferred embodiment, a plurality of candidate targets are tested. In a preferred
5 embodiment the plurality of candidate targets includes at least 10 , 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , or 10^8 candidate targets.

In a preferred embodiment, the target interacts with, e.g., binds, and preferably modifies,
10 the substrate. Modify includes making or breaking a bond, e.g., a non-covalent or covalent bond, in the surrogate ligand (or in the signal-generating entity itself). Modification includes cleavage, degradation, hydrolysis, a change in the level of phosphorylation labeling, ligation, synthesis, and similar reactions. Modification can include physical changes in phase, changes in aggregation, or polymerization.

15 In a preferred embodiment, the method further includes:
selecting a candidate target; and confirming that candidate target modified the target.

In a preferred embodiment, the method further includes:
selecting a candidate target; and contacting the candidate target with a cell, e.g., a cultured
20 cell, or an animal, and, optionally, determining if the candidate target has an effect on the cell or animal.

In a preferred embodiment, the method further includes: purifying a candidate target;
crystallizing a candidate target; evaluating a physical property of a candidate target, e.g., molecular
25 weight, isoelectric point, sequence (where relevant), or crystal structure.

In a preferred embodiment, the method further includes: optimizing a property of a chosen
candidate target, e.g., optimizing affinity for the substrate, altering molecular weight, e.g.,
decreasing molecular weight, or altering, e.g., increasing, solubility. Optimization can be
30 performed using known methods or methods disclosed herein,

In a preferred embodiment, the change in heat is measured with a microcalorimeter.

In another aspect, the invention features, a method of analyzing a target, e.g., analyzing an
5 interaction of a target and a second entity. The method includes:

providing a reaction mixture containing the target,
allowing the interaction to proceed, wherein the interaction is linked to a linking interaction,
e.g., a linking reaction, e.g., the release of a surrogate-ligand or a change in conformation;
allowing a product of the linking reaction to enter a second reaction, e.g., the cleavage or
10 degradation of a surrogate ligand; and
measuring the heat change from the second reaction,
thereby analyzing an interaction of the target.

In a preferred embodiment the linking reaction or the second reaction can include a change
15 in phase.

In a preferred embodiment one or more additional reactions can be interposed between the
linking reaction and the second reaction.

20 In a preferred embodiment the interaction of the target can be, e.g., an interaction between
the target and another molecule, e.g., a ligand or a solute molecule, or an interaction of a first
moiety of the target with a second moiety of the target, e.g., autophosphorylation, or a change in
the conformation of the target, e.g., the secondary, tertiary, or quaternary, structure of the target.

25 In a preferred embodiment: the reaction mixture is not transparent; the reaction mixture is
colored; the reaction mixture is turbid; the reaction mixture contains a substance which interferes
with fluorescent or colorimetric detection; the reaction mixture is not a pure solution, e.g., it
contains products other than the target. In a preferred embodiment the reaction mixture contains: a
substance which interferes with radioactive analysis; a substance which interferes with
30 spectrophotometric analysis, e.g., NMR analysis.

In a preferred embodiment the change in heat is measured with a microcalorimeter.

In another aspect, the invention features, a method of analyzing a test ligand, target, or an interaction between the two. The method includes:

- 5 providing a reaction mixture containing a surrogate ligand and a target,
 contacting the reaction mixture with the test ligand and with a signal-generating entity;
 wherein the signal-generating entity is present with the surrogate ligand under conditions
 which allow it to interact with surrogate ligand, e.g., with surrogate ligand which has been
 displaced from the target by binding of the test ligand to the target; and
10 measuring the change in heat in the reaction mixture,
 thereby analyzing a test ligand, target, or an interaction between the two.

In preferred embodiments, the surrogate ligand exhibits negative heterotropic linkage with
respect to a test ligand which can bind the target, (i.e., it is displaced upon binding of the test ligand
15 to the target). This is the preferred embodiment and the subject of most of the discussion herein.
However, the invention also includes embodiments wherein the surrogate ligand binds the target
upon binding of the test ligand, thereby reducing the level of free surrogate ligand and thereby
providing less surrogate ligand to interact with the signal-generating entity.

20 In preferred embodiments, the interaction between the signal-generating entity and the
surrogate ligand occurs more readily between the signal-generating entity and free (as opposed to
target-bound) surrogate ligand. By way of example the interaction between the signal-generating
entity and free (as opposed to target-bound) surrogate ligand occurs at least 2, 5, 10, 10^2 , 10^3 , 10^4 ,
 10^5 , 10^6 , 10^7 , or 10^8 fold more readily between the signal-generating entity and free (as opposed to
25 target-bound) surrogate ligand. However, the invention also includes embodiments wherein the
interaction between the signal-generating entity and the surrogate ligand occurs more readily
between the signal-generating entity and target-bound (as opposed to free) surrogate ligand. By
way of example the interaction between the signal-generating entity and target-bound (as opposed
to free) surrogate ligand occurs at least 2, 5, 10, 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , or 10^8 fold more readily
30 between the signal-generating entity and target-bound (as opposed to free) surrogate ligand.

In preferred embodiment, the surrogate ligand is an ion, e.g., a proton. In a preferred embodiment the signal-generating entity is a buffer molecule, e.g., with a relatively large heat of ionization, e.g., Tris HCL.

5 In a preferred embodiment, the surrogate ligand is factor which modulates, e.g., increases or decreases, the activity of the signal-generating entity. By way of example, the surrogate ligand can be a metal ion which activates (or inhibits) an enzyme which is the signal-generating entity.

10 In a preferred embodiment, the signal-generating entity interacts with, e.g., binds, and preferably modifies, surrogate ligand, e.g., free surrogate ligand. Modify includes making or breaking a bond, e.g., a non-covalent or covalent bond, in the surrogate ligand (or in the signal-generating entity itself). Modification includes cleavage, degradation, hydrolysis, a change in the level of phosphorylation labeling, ligation, synthesis, and similar reactions. Modification can also include physical changes in phase, changes in aggregation, or polymerization.

15

In a preferred embodiment, the target is a protein or polypeptide, the surrogate ligand is a nucleic acid, the signal-generating entity is an enzyme which cleaves a bond in a nucleic acid, e.g., a nuclease.

20

In a preferred embodiment, the method further includes:
selecting a ligand which interacts with the target; and confirming that the ligand interacts with, e.g., binds, to the target, in a second test, e.g., one in which the surrogate ligand is not present.

25

In a preferred embodiment, the method further includes:
selecting a test ligand which interacts with the target; and confirming that the test ligand interacts with, e.g., binds, to the target by contacting the ligand with the target *in vitro*, e.g., in the absence of the surrogate ligand.

In a preferred embodiment, the method further includes:

selecting a ligand which interacts with the target; and contacting the ligand with a cell, e.g., a cultured cell, or an animal, and, optionally, determining if the ligand has an effect on the cell or animal.

5 In a preferred embodiment, the method further includes: purifying a test ligand; crystallizing a test ligand; evaluating a physical property of a test ligand, e.g., molecular weight, isoelectric point, sequence (where relevant), or crystal structure.

In a preferred embodiment the method further includes: optimizing a property of a chosen test ligand, e.g., optimizing affinity for the target, altering molecular weight, e.g., decreasing
10 molecular weight, or altering, e.g., increasing, solubility. Optimization can be performed using known methods or methods disclosed herein,

In a preferred embodiment, the surrogate ligand, e.g., a surrogate ligand, e.g., a nucleic acid, is amplified, e.g., with PCR or more preferably with an isothermal amplification method, prior to
15 interaction with the signal-generating entity.

In a preferred embodiment the change in heat is measured with a microcalorimeter.

In a preferred embodiment, the signal-generating entity interacts directly with the surrogate
20 ligand. In other embodiments is interacts indirectly, e.g., it interacts with an amplification product generated from the surrogate ligand or it acts on the product of a reaction between the surrogate ligand and another entity.

25 In another aspect, the invention features, a method of analyzing a target, a test ligand, or the interaction between the two. The method includes:

providing a reaction mixture containing a surrogate ligand and the target;
contacting the reaction mixture with the test ligand and with a signal-generating entity;
wherein the signal-generating entity is present with the surrogate ligand under conditions
30 which allow it to interact with free surrogate ligand, e.g., with surrogate ligand which has been displaced from the target by binding of the test ligand; and

measuring the change in heat in the reaction mixture,
thereby analyzing a test ligand, target, or an interaction between the two.

In preferred embodiments, the surrogate ligand exhibits negative heterotropic linkage with
5 respect to a test ligand which can bind the target, (i.e., it is displaced upon binding of the test ligand
to the target). This is the preferred embodiment and the subject of most of the discussion herein.
However, the invention also includes embodiments wherein the surrogate ligand binds the target
upon binding of the test ligand, thereby reducing the level of free surrogate ligand and thereby
providing less surrogate ligand to interact with the signal-generating entity.

10 In preferred embodiments, the interaction between the signal-generating entity and the
surrogate ligand occurs more readily between the signal-generating entity and free (as opposed to
target-bound) surrogate ligand. By way of example the interaction between the signal-generating
entity and free (as opposed to target-bound) surrogate ligand occurs at least 2, 5, 10, 10^2 , 10^3 , 10^4 ,
15 10^5 , 10^6 , 10^7 , or 10^8 fold more readily between the signal-generating entity and free (as opposed to
target-bound) surrogate ligand. However, the invention also includes embodiments wherein the
interaction between the signal-generating entity and the surrogate ligand occurs more readily
between the signal-generating entity and target-bound (as opposed to free) surrogate ligand. By
way of example the interaction between the signal-generating entity and target-bound (as opposed
20 to free surrogate ligand occurs at least 2, 5, 10, 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , or 10^8 fold more readily
between the signal-generating entity and target-bound (as opposed to free) surrogate ligand.

In a preferred embodiment, the signal-generating entity interacts with, e.g., binds, and
preferably modifies, free surrogate ligand. Modify includes making or breaking a bond, e.g., a
25 non-covalent or covalent bond, in the surrogate ligand (or in the signal-generating entity itself).
Modification includes cleavage, degradation, hydrolysis, a change in the level of phosphorylation
labeling, ligation, synthesis, and similar reactions. Modification can include physical changes in
phase, changes in aggregation, or polymerization.

30 In a preferred embodiment, the signal-generating entity is a degradative enzyme.

In a preferred embodiment, the surrogate ligand is a nucleic acid and the signal-generating entity is an enzyme which modifies a nucleic acid, or uses the nucleic acid for a substrate or template, e.g., the signal-generating entity an enzyme, e.g., a nuclease, e.g., a DNase, e.g., an endonuclease or an exonuclease, a polymerase, e.g., a DNA polymerase: the signal-generating
5 entity modifies a protein, e.g., by making or breaking a covalent or non-covalent bond in the surrogate ligand (or itself) e.g., it cleaves a peptide bond, e.g., is a protease, and the surrogate ligand includes a peptide bond, e.g., is a protein.

In a preferred embodiment, the method further includes:

10 selecting a ligand which interacts with the target; and confirming that the test ligand interacts with, e.g., binds, to the target in a second test, e.g., one in which the surrogate ligand is not present.

In a preferred embodiment, the method further includes:

15 selecting a test ligand which interacts with the target; and confirming that the ligand interacts with, e.g., binds, to the target by contacting the test ligand with the target *in vitro*, e.g., in the absence of the surrogate ligand.

In a preferred embodiment, the method further includes:

20 selecting a test ligand which interacts with the target; and contacting the test ligand with a cell, e.g., a cultured cell, or an animal, and, optionally, determining if the test ligand has an effect on the cell or animal.

In a preferred embodiment, the method further includes: purifying a test ligand;

25 crystallizing a test ligand; evaluating a physical property of a test ligand, e.g., molecular weight, isoelectric point, sequence (where relevant), or crystal structure.

In a preferred embodiment, the method further includes: optimizing a property of a chosen test ligand, e.g., optimizing affinity for the target, altering molecular weight, e.g., decreasing
30 molecular weight, or altering, e.g., increasing, solubility. Optimization can be performed using known methods or methods disclosed herein,

In a preferred embodiment, the reaction mixture is not transparent; the reaction mixture is colored; the reaction mixture is turbid; the reaction mixture contains a substance which interferes with fluorescent or colorimetric detection; the reaction mixture is not a pure solution, e.g., it
5 contains products other than the target. In a preferred embodiment the reaction mixture contains: a substance which interferes with radioactive analysis; a substance which interferes with spectrophotometric analysis, e.g., NMR analysis.

In a preferred embodiment, the surrogate ligand, e.g., a nucleic acid, is amplified, e.g., with
10 PCR or more preferably with an isothermal amplification method, prior to interaction with the signal-generating entity.

In a preferred embodiment, the change in heat is measured with a microcalorimeter.

In a preferred embodiment, the signal-generating entity interacts directly with the surrogate
15 ligand. In other embodiments it interacts indirectly, e.g., it interacts with an amplification product generated from the surrogate ligand or it acts on the product of a reaction between the surrogate ligand and another entity.

20 In another aspect, the invention features, a method of analyzing a target, a test ligand, or the interaction between the two. The method includes:

providing a reaction mixture containing a surrogate ligand, which is a nucleic acid, and the target;

25 contacting the reaction mixture with the test ligand and with a signal-generating entity, which is a molecule which makes or breaks a bond, e.g., a covalent or non-covalent bond, in the surrogate ligand;

wherein the signal-generating entity is present with the surrogate ligand under conditions which allow it to interact with free surrogate ligand, e.g., with surrogate ligand which has been
30 displaced from the target by binding of the test ligand; and

measuring the change in heat in the reaction mixture,

thereby analyzing a test ligand, target, or an interaction between the two.

In preferred embodiments, the surrogate ligand exhibits negative heterotropic linkage with respect to a test ligand which can bind the target, (i.e., it is displaced upon binding of the test ligand to the target).

In preferred embodiments, the interaction between the signal-generating entity and the surrogate ligand occurs more readily between the signal-generating entity and free (as opposed to target-bound) surrogate ligand. By way of example the interaction between the signal-generating entity and free (as opposed to target-bound) surrogate ligand occurs at least 2, 5, 10, 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , or 10^8 fold more readily between the signal-generating entity and free (as opposed to target-bound) surrogate ligand.

In a preferred embodiment, the signal-generating entity is a degradative enzyme.

In a preferred embodiment, the signal-generating entity is an enzyme which modifies a nucleic acid, or uses the nucleic acid for a substrate or template, e.g., the signal-generating entity an enzyme, e.g., a nuclease, e.g., an endonuclease or an exonuclease, a polymerase, e.g., a DNA polymerase.

In a preferred embodiment, the method further includes:

selecting a test ligand which interacts with the target; and confirming that the test ligand interacts with, e.g., binds, to the target in a second test, e.g., one in which the surrogate ligand is not present.

In a preferred embodiment, the method further includes:

selecting a ligand which interacts with the target; and confirming that the test ligand interacts with, e.g., binds, to the target by contacting the test ligand with the target *in vitro*, e.g., in the absence of the surrogate ligand.

In a preferred embodiment, the method further includes:

selecting a test ligand which interacts with the target; and contacting the test ligand with a cell, e.g., a cultured cell, or an animal, and, optionally, determining if the ligand has an effect on the cell or animal.

5 In a preferred embodiment, the method further includes: purifying a test ligand; crystallizing a test ligand; evaluating a physical property of a test ligand, e.g., molecular weight, isoelectric point, sequence (where relevant), or crystal structure.

10 In a preferred embodiment, the method further includes: optimizing a property of a chosen test ligand, e.g., optimizing affinity for the target, altering molecular weight, e.g., decreasing molecular weight, or altering, e.g., increasing, solubility. Optimization can be performed using known methods or methods disclosed herein,

15 In a preferred embodiment, the surrogate ligand is amplified, e.g., with PCR or more preferably with an isothermal amplification method, e.g., prior to interaction with the signal-generating entity.

In a preferred embodiment, the change in heat is measured with a microcalorimeter.

20 In a preferred embodiment, the signal-generating entity interacts directly with the surrogate ligand. In other embodiments it interacts indirectly, e.g., it interacts with an amplification product generated from the surrogate ligand or it acts on the product of a reaction between the surrogate ligand and another entity.

25 In another aspect, the invention features a library of interaction candidates, e.g., a library of candidate substrates or test ligands as described herein. Preferably, the library includes at least one member which is known to interact with a target.

30 In a preferred embodiment, the library is: a substrate library; a cofactor library; a carbohydrate biosynthesis and/or degradation library; a purine and pyrimidine biosynthesis and/or

degradation library; an amino acid biosynthesis and/or degradation library; a lipid biosynthesis and/or degradation library; a vitamin and/or hormone library; a nucleic acid, e.g., DNA library; or a natural product library, e.g., a bacterial natural product library.

5 In a preferred embodiment, a library member is a species which has potential to interact with a target, e.g., a target protein. Preferably, a library member is a candidate substrate or a test ligand.

10 In a preferred embodiment, a library member is selected from the group consisting of: an enzyme substrate, a metabolite, a cofactor, a natural product (e.g., a bacterial natural product), a carbohydrate, a polysaccharide, a nucleic acid (e.g., a nucleoside or nucleotide precursor, a double-stranded (ds) or single-stranded (ss) DNA molecule, a circular nucleic acid, a super-coiled nucleic acid), an amino acid, (e.g., a D- or L-amino acid or a precursor thereof), a vitamin, a hormone, a lipid, a small organic molecule, a metals, a peptide, a protein, a lipid, a glycoprotein, a glycolipid, a
15 transition state analog and combinations thereof.

In a preferred embodiment, the library includes a plurality of members having a common characteristic, e.g., all members of the plurality are enzyme cofactors; substrates for, e.g., biosynthetic or degradative enzymes (e.g., protease substrates), including carbohydrates,
20 nucleoside/nucleotides, amino acids, lipids; vitamins; hormones; nucleic acids; e.g., DNA molecules; or natural products, e.g., bacterial natural products. The library can include any metabolite, precursor, or intermediate of the members listed above. The library can include any combination of members having different characteristics. For example, a library of cofactors can be combined with a library of substrates for biosynthetic or degradative enzymes.

25

In a preferred embodiment, the library includes at least 10, 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , or 10^8 compounds.

30 In a preferred embodiment, the library includes at least 10, 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , or 10^8 of the library members which share a structural or functional characteristic. In other embodiments, the library can include combinations of members sharing structural or functional

characteristics. For example, the library can include at least 10 , 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , or 10^8 of the library members which share a structural or functional characteristic and at least 10 , 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , or 10^8 of the library members which share a different structural or functional characteristic.

5

In a preferred embodiment, a combination of two, or more, libraries is tested with a target simultaneously. By way of example, the target can be tested against each (or some) members of a first library, e.g., a cofactor library, and each (or some) members of a second library, e.g., a library of potential substrates. Thus, in the case of two libraries with a first library having 50 members (first₁, first₂, ... first₅₀) and a second library having 50 members (second₁, second₂, ... second₅₀....) the target is tested against all or a plurality of the novel combinations, e.g., against (first₁, second₁), (first₁ second₂) ... (first₁, second₅₀), and so on.

Other features and advantages of the invention will be apparent from the following description and from the claims.

15

Brief Description of the Drawings

Figure 1 depicts a schematic diagram of the target-mediated conversion of a test substrate(s) into a product(s). Such conversion generates a heat signal. This method measures the heat output generated from the interaction between a test substrate and a target (e.g., a target protein). As shown, the target-mediated conversion of a test substrate(s) into a product(s) generates a heat signal. The heat signal can be detected calorimetrically.

20

Figure 2 depicts a schematic diagram of the molecular detection switch to detect binding of a test ligand. This method uses the generation of a heat signal to identify the interaction of a test ligand with a target (e.g., a target protein). As shown, a surrogate ligand is incubated in the presence of the target such that an interaction (e.g., binding) occurs. Upon binding of the test ligand, the surrogate ligand is displaced. The free surrogate ligand (i.e., the displaced surrogate ligand) serves as a substrate for a signal-generating entity, e.g., an enzyme, in such a manner that a heat signal is generated. An important feature of the signal-generating entity is that it produced a

25

30

large amount of heat per unit time (i.e., it amplifies the binding signal). The heat signal can be detected calorimetrically.

5 *Figures 3A-3B* depict a read-out of the rate of heat generated ($\mu\text{cal/sec}$) during a substrate screen with hexokinase with respect to time (sec). Figure 3A shows the heat flow in the presence of a substrate, which reaches a maximum soon after the addition of enzyme to the reaction cell and then decays to the baseline as the level of substrate is depleted. Figure 3B shows a control (carbohydrate library minus substrate)

10 *Figure 4* depicts the experimental flow chart for the substrate screen with hexokinase.

Figure 5a(i) shows the heat released upon binding of hexokinase to glucose over time. As time proceeds, the fixed amount of hexokinase in the cell is bound, so additional glucose produces less heat. 5 μ l injections of a 5 μ M solution of glucose were titrated into the calorimetric cell containing 2 ml of a 50 nM solution of hexokinase. Because no ATP is present, the glucose merely binds to the protein. The heat released from each injection was measured and the binding constant calculated from those measurements.

Figure 5a(ii) shows heat released as hexokinase phosphorylates glucose in the presence of ATP, converting ATP to ADP. A single 5 μ l injection of a 20 μ M solution of hexokinase was titrated into the calorimetric cell containing 2 ml of a solution of 100 μ M glucose and 1 mM ATP. A large negative heat is observed as the hexokinase acts on the glucose. We integrated the heat evolved with respect to time to follow the time course of the reaction.

Figure 5b compares rates of reaction of glucose and ATP catalyzed by hexokinase measured by two different techniques: UV spectrophotometry and calorimetry. The heat output of the reaction from figure 5a (ii) is plotted with respect to time. The reaction was also measured using a second assay, both methods give the same rates for the reaction (within experimental error).

Figure 6 compares rates of reaction of thrombin-catalyzed cleavage of a labeled peptide substrate (SAR-PRO-ARG-paranitronalide) with UV spectrophotometry and calorimetry. Upon cleavage, the PNA (paranitronalide) label absorbs more UV radiation and heat is evolved. 2 ml of a solution with 186 nM thrombin and 250 μ M substrate were allowed to react, and the reaction was monitored calorimetrically and spectrophotometrically. Again, nearly identical rates were calculated using the different assays.

Figures 7A-7D demonstrate the use of the present invention to deconvolute a mixture of compounds. Hexokinase and glucose were present in each test. Various mixtures of cofactors were added to each test. Only when ATP was present in the mixture was a significant amount of heat generated. 5 μ l injections of a 20 μ M solution of hexokinase were titrated into a solution of 100 μ M glucose and one or more "cofactors", all at 1 mM concentration. In the initial experiment with the entire library of 15 cofactors present, enzymatic turnover was observed (as

in figure 5a (ii)). We were then able to successfully separate out the cofactors in subsequent experiments to determine which one was actually necessary to allow the hexokinase to turn over the glucose. A large negative heat is observed in the first injection of protein whenever ATP, the correct cofactor, is present in the mix of cofactors in the cell. Only tiny heats of dilution are observed when ATP is absent.

Figure 8 demonstrates calorimetric measurement of hexokinase-catalyzed glucose phosphorylation in the presence of a complex mixture of natural products. 5 μ l injections of a 20 μ M solution of hexokinase were titrated into solutions of 100 μ M glucose and 1 mM ATP and increasing concentrations of tea. Tea solutions can simulate natural product extracts, *i.e.*, complex mixtures. Significant enzymatic activity (turnover) was observed at all but the highest concentrations of tea.

Figure 9 demonstrates the use of calorimetry to aid in determining function of cryptic proteins. *E. coli* protein YJEQ binds to GTP analog GTP-gamma-S. A K_d of 115 μ M was determined. 5 μ l injections of an 11 mM GTP-gamma-S solution were titrated into 2 ml of a solution containing 385 μ M of an *E. coli* protein for which no function was previously known. As in figure 5a (i), the experiment shows that the protein binds this molecule (an analog of GTP), allowing us to putatively assign GTP-binding properties to this protein.

Detailed Description

The absorption or evolution of heat is a universal property of chemical reactions. Methods described herein link an interaction, e.g., binding, of a test compound or an interactor, e.g., a test
15 ligand or a candidate substrate, with a target (e.g., a target macromolecule, e.g., a target protein or nucleic acid) to a change in heat. The heat output is detected by calorimetry. This allows analysis of the interaction without imposing sharply constraining limitations on the type, range, or specific identity of the activity of the target. By way of example, it allows for the identification of an interactor, e.g., a substrate, for a target having an unknown, poorly characterized, or merely
20 putative or broadly described activity. E.g., where the target is an enzyme, methods of the invention detect a change in heat generated upon conversion of a test substrate(s) into a product(s) or, where the target and interactor are ligand and counter-ligand, upon binding. Some embodiments of the invention require no assumptions about the nature of the target and its interaction with its interactor, e.g., its naturally occurring ligand, substrate, or binding partner. Other methods of the
25 invention incorporate knowledge of or assumptions about the target (and/or interactor) to guide in the choice of potential interactors. E.g., embodiments of the invention use genomic, or other bioinformatic analyses of the target to optimize and/or prioritize the choice of interactors against which to test the target.

Libraries of interaction candidates, e.g., a library of candidate substrate or test ligands as
30 described herein, are also within the scope of the present invention. The methods and compositions, e.g., libraries, of the present application can be used for diagnostic testing, for

research purposes, or to screen for agents, e.g., pharmaceutical agents. Agents, e.g., pharmaceutical agents, identified using the methods described herein are also within the scope of the present invention.

5 In order that the present invention may be more readily understood, certain terms are first defined.

As used herein, a "test compound" also referred to as an "interactor", is a species which has potential to interact with a target, e.g., a target macromolecule, (e.g., a protein or nucleic acid). The test compound can be a candidate substrate or a test ligand. A test compound can be any agent,
10 including without limitation small organic molecules, metals, peptides, proteins, lipids, glycoproteins, glycolipids, carbohydrates, polysaccharides, nucleic acids (e.g., a nucleoside or nucleotide precursor, a ds or ss DNA molecule, a circular nucleic acid, a super-coiled nucleic acid), an amino acid, (e.g., a D- or L-amino acid or a precursor thereof), a vitamin, a hormone, enzyme substrates, metabolites, transition state analogs, cofactors, natural products (e.g., bacterial natural
15 products) and combination thereof. A library can comprise a plurality of test compounds.

As used herein, a "mixture" or "reaction mixture" can be a complex combination of substances, e.g., impure samples, such as suspensions, natural product extracts, cell homogenates, cell lysates or cell extracts, whole cells, reconstituted systems, biochemical mixtures, biological samples, tissue samples, biological fluids, or colored solutions, which may include more than one
20 test compound.

As used herein, a "candidate substrate" is a substance which gives rise to a different chemical entity when acted on. Exemplary candidate substrates include an enzyme substrate; a metabolite; a cofactor (e.g., a group transfer and energy coupling molecule); a natural product, e.g., a bacterial natural product; a carbohydrate; a polysaccharide; a nucleic acid, e.g., a nucleoside or
25 nucleotide precursor, a double-stranded (ds) or single-stranded (ss) DNA molecule; an amino acid, e.g., a D- or L-amino acid or a precursor thereof; a vitamin; a hormone; a lipid, among others.

As used herein, a "test ligand" is a member of a combinatorial library; is a drug candidate; is from a library of compounds; a library of natural compounds, e.g., fungal products or fermentation products; organic synthesis libraries. In a preferred embodiment the ligand is: a
30 polypeptide which has been expressed from a nucleic acid from a population of nucleic acids, e.g., from a cDNA library, a differentially expressed cDNA library, a genomic library, a library

produced by expression profiling, a library which has been enriched for species expressed in a predetermined tissue, a predetermined time of development, or in a predetermined disorder or in the absence of a disorder, a plurality of nucleic acids which have been selected by hybridization, e.g., by hybridization to an ordered two-dimensional array of probes, a library which was produced
5 after the treatment of a cell or organism with a treatment, e.g., a drug.

As used herein, a "library" is a collection substances which can potentially interact with a target. Preferably, the library includes at least one member which is known to interact with a target.

As used herein, a "substrate library" is a collection of compounds for which targets. e.g.,
10 proteins, e.g., those of unknown function (also referred to herein as "unknowns") can be screened against for potential interaction, e.g., enzymatic activity. Interaction, e.g., enzymatic activity will result in a change in heat output which will be detected by the calorimeter.

As used herein, the term "target" refers to any molecule of interest. In a preferred embodiment: the target is a protein or polypeptide, e.g., a naturally occurring protein or fragment
15 thereof; a protein of unknown function; a protein for which the ligand, substrate, or other interacting molecule is not known. The target can be nucleic acid, e.g., a DNA or RNA (e.g., structured RNA, e.g., a ribozyme). Targets include molecules (e.g., peptides, proteins or nucleic acids), having known or unknown structure or function. In a preferred embodiment, the target is a protein without a catalytic activity, with no known catalytic activity, or has a catalytic activity
20 which is difficult to measure. A target can also be a carbohydrate, a polysaccharide, and a glycoprotein, among others.

As used herein, the term "surrogate ligand" refers to an agent that interacts with (e.g., binds to) a target, e.g., a target protein. The surrogate ligand can be naturally associated with the target, or not naturally associated with the target. In a preferred embodiments the surrogate ligand has a
25 K_D for the target of at least 10^{-1} , 10^{-2} , 10^{-4} , 10^{-6} , 10^{-8} , 10^{-10} , 10^{-12} , 10^{-15} , 10^{-20} , 10^{-25} , $10^{-30} M^{-1}$. Preferably, the surrogate ligand meets the following criteria: (1) the surrogate ligand exhibits a heterotropic linkage with respect to a test ligand (i.e., it must be displaced upon binding of a test ligand (negative heterotropic linkage), or its binding to a target is enabled with respect to the test ligand (positive heterotropic linkage); and 2) the surrogate ligand in its "free" or displaced form
30 serves as a switch to generate an amplified signal. For example, the displaced surrogate ligand serves as a substrate for an enzyme. Preferably, the surrogate ligand can interact with (e.g., bind

to) any surface or internal sequences, or conformational domains of the target. In other embodiments, the surrogate ligand can catalytically alter the target, or alter the functional activity of the target. Examples of natural surrogate ligands include anions, cations, protons, water and other solution phase components are found in association with a target. Examples of non-naturally occurring surrogate ligands include synthetic protein, a peptide and nucleic acid sequences (e.g., a DNA or an RNA molecule).

A surrogate ligand of the invention is not limited to an agent that interacts with (e.g., binds to) a recognized functional region of the target protein, e.g. the active site of an enzyme, the antigen-combining site of an antibody, the hormone-binding site of a receptor, a cofactor-binding site, and the like.

In a preferred embodiment, the surrogate ligand is a nucleic acid molecule (also referred to herein as a "surrogate nucleic acid ligand"). As used herein, the term "nucleic acid molecule" refers to DNA, RNA, single-stranded or double-stranded and any chemical modifications thereof. Exemplary modifications include, but are not limited to, those which provide other chemical groups that incorporate additional charge, polarizability, hydrogen bonding, and electrostatic interaction to the nucleic acid. Such modifications include, but are not limited to, 2'-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitutions of 4-thiouridine, substitution of 5-bromo or 5-iodo-uracil, backbone modifications, methylations, base-pairing combinations such as the isobases isocytidine and isoguanidine, as well as 3' and 5' modifications such as capping.

As used herein, the term "surrogate nucleic acid ligand" includes a nucleic acid molecule comprising two to forty nucleotides, preferably ten to thirty nucleotides, more preferably, fifteen to twenty-five nucleotides, and most preferably, twenty nucleotides. Accordingly, in preferred embodiments, the surrogate ligand is an oligonucleotide. In one embodiment, the surrogate nucleic acid ligand is identified using the SELEX procedure as described in detail below, and in Gold *et al.* (1995) *Annu. Rev. Biochem.* 64:763-797 entitled "Diversity of Oligonucleotide Functions"; US 5,270,163 entitled "Methods for Identifying Nucleic Acid Ligands" issued in December 14, 1993 to Gold *et al.*; US 5,567,588 entitled "Systemic Evolution of Ligands by Exponential Enrichment Solutions Selex" issued in October 22, 1996 to Gold *et al.*; US 5,763,177 entitled "Systemic Evolution of Ligands by Exponential Enrichment: Photoselection of Nucleic Acid Ligands and Solutions Selex" issued in June 9, 1998 to Gold *et al.*; US 5, 874,219 entitled "Method for

Detecting a Target Compound in a Substance Using a Nucleic Acid Ligand" issued in February 23, 1999 to Drolet, D. *et al.*; the contents of all of which are hereby expressly incorporated by reference.

As used herein, the term "signal-generating entity" is an entity which interacts with a surrogate ligand in a non-isothermal process, preferably an exothermic process. Preferably, the signal-generating entity amplifies a signal generated by a test ligand. For example, the signal-generating entity may interact with (e.g., binds to) and preferably, modify a surrogate ligand in a manner that gives rise to a signal, e.g., heat output. A typical signal-generating entity is an enzyme which undergoes an exothermic or endothermic reaction with a surrogate ligand.

Preferably, the signal-generating entity interacts more readily with a free surrogate ligand, as opposed to a surrogate ligand bound to a target. In certain embodiments, the signal-generating entity modifies the free (as opposed to target-bound) surrogate ligand by, e.g., forming or breaking a covalent or a non-covalent bond. For example, the modification step may involve cleavage, degradation, phosphorylation, polymerization, or any other event that generates a signal, e.g., a heat signal. The signal-generating entity can be a degradative enzyme (e.g., a nuclease or a protease). Alternatively, the signal-generating entity can be a polymerizing enzyme, e.g., a polymerase. For example, in those embodiments, where the free surrogate ligand is a DNA molecule, the signal-generating entity can be a nuclease, such as a staphylococcal nuclease (SNase), *Serratia marcescens* nuclease (SNase), bovine pancreatic nuclease (DNase I), or human (type IV) nuclease. Alternatively, the signal-generating entity can be a polymerase, e.g., a Tac polymerase. In those embodiments, where the free surrogate ligand is an RNA molecule, the signal-generating entity can be a ribonuclease (e.g., an RNase). In those embodiments, where the free surrogate ligand is a protein or a peptide, the signal-generating entity can be a protease. Exemplary proteases include, but are not limited to, trypsin, chymotrypsin, V8 protease, elastase, carboxypeptidase, proteinase K, thermolysin, papain and subtilisin. In those embodiments where the surrogate ligand is a metal ion, an enzyme requiring the metal for activation can be used as the signal-generating entity.

In other embodiments, the signal-generating entity can be a solution (e.g., a buffer solution) that amplifies the molecular events which occur when a test ligand binds to a target (e.g., a target protein). For example, many target proteins release or bind a large number of protons when they bind to a test ligand. These release or absorption events are said to be "linkage" events. The linkage process can be amplified by introducing in the solution a buffer molecule with a large heat

of ionization, for example, Tris HCl. In yet other embodiments, the signal-generating entity can be a change in phase, or an aggregation or polymerization of material.

As used herein, the interaction of a first molecule with a second can include a change in the association of the two molecules, e.g., an increase or decrease, in the binding of the two molecules or a modification of either or both of the molecules. As used herein modification includes, making or breaking a bond, e.g., a non-covalent or covalent bond. It includes cleavage, degradation, hydrolysis, a change in the level of phosphorylation, labeling, ligation, synthesis, and similar reactions. Modification can include physical changes in phase, changes in aggregation, or polymerization.

In the case of the interaction with a signal-generating entity the modification is not isothermal, and is preferably exothermic.

As used herein, the phrase "analyzing a ligand" can include one or more of: determining if the ligand binds to the target; evaluating the affinity of a test ligand for a target.

Generation of Targets

The targets used in the methods of the present invention can be any molecule of interest. Preferably, the target is a protein or polypeptide (also referred to herein as a "target protein"), e.g., a naturally occurring protein or fragment thereof; a protein of unknown function; a protein for which the ligand, substrate, or other interacting molecule is not known. Exemplary target proteins include, without limitation, receptors, enzymes, oncogene products, tumor suppressor gene products, transcription factors, and infectious proteins (e.g., proteins obtained from an infectious organism, e.g., viral, parasitic, bacterial, and/or fungal proteins). Furthermore, target proteins may comprise wild type proteins, or, alternatively, mutant or variant proteins, including those with altered stability, activity, or other variant properties, or hybrid proteins to which foreign amino acid sequences, e.g. sequences that facilitate purification have been added (e.g., a glutathione S-transferase (GST) moiety).

The target proteins can be either in purified form or in impure form (e.g., as part of a complex mixture of proteins and other compounds as described herein). In certain embodiments, the target protein can be a recombinant protein or a biochemical isolate. For example, the target can be any protein encoded by a gene isolated from a prokaryotic or eukaryotic organism. The isolated gene can be cloned into an expression vector, and introduced into a suitable host cell under

conditions which allow expression of the cloned genes by practicing standard molecular biology techniques (Ausubel, F. et al., eds. *Current Protocols in Molecular Biology* 1999, J. Wiley: New York.; Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). Vectors can be, e.g., plasmids, viral vectors, among others. Preferably, the
 5 vectors are modified, e.g., by linking the gene encoding the target protein to appropriate regulatory sequences, such that appropriate expression of the target protein is obtained. Examples of regulatory sequences include promoters, enhancers and other expression control elements (e.g., poly-adenylation signals) (see e.g., Goeddel; (1990) *Gene Expression Technology: Methods in*
 10 *Enzymology* 185, Academic Press, San Diego, CA).

Targets may be obtained from a prokaryotic or a eukaryotic organism, such as microorganisms (e.g., bacteria, viruses, parasites), vertebrate or invertebrate animals (e.g., mammals, e.g., humans).

Exemplary prokaryotic organisms include: Aquifex aeolicus, Pyrococcus horikoshii,
 15 Bacillus subtilis, Treponema pallidum, Borrelia burgdorferi, Helicobacter pylori, Archaeoglobus fulgidus, Methanobacterium thermo., Escherichia coli, Mycoplasma pneumoniae, Synechocystis sp. PCC6803, Methanococcus jannaschii, Mycoplasma genitalium, Haemophilus influenzae, Rickettsia prowazekii, Pyrococcus abyssi, Bacillus sp. C-125, Pseudomonas aeruginosa, Ureaplasma urealyticum, Pyrobaculum aerophilum, Pyrococcus furiosus, Mycobacterium
 20 tuberculosis H37Rv, Mycobacterium tuberculosis CSU93, Neisseria gonorrhea, Neisseria meningitidis, Streptococcus pyogenes, Borellia burgdorferi, Caulobacter crescentus, Chlorobium tepidum, Deinococcus radiodurans, Enterococcus faecalis, Legionella pneumophila, Mycobacterium avium, Mycobacterium tuberculosis, Methanococcus jannaschii, Neisseria meningitides, Pseudomonas putida, Porphyromonas gingivalis, Salmonella typhimurium,
 25 Shewanella putrefaciens, Streptococcus pneumoniae, Thermotoga maritime, Treponema denticola, Thiobacillus ferrooxidans, Vibrio cholerae, Clostridium acetobutylicum, Enterococcus faecium, Mycobacterium leprae, Pseudomonas aeruginosa, Staphylococcus aureus, Bacillus sp., Bartonella henselae, Bordetella pertussis, Campylobacter jejuni, Francisella tularensis, Halobacterium salinarium Institute, Listeria monocytogenes, Mycobacterium tuberculosis Sanger, Mycoplasma
 30 mycoides, Neisseria meningitidis strain, Streptomyces coelicolor, Rickettsia prowazekii, Sulfolobus solfataricus, Synechocystis sp. PCC6803, Thermoplasma acidophilum, Yersinia pestis,

Xylella fastidiosa, *Actinobacillus actinomyces*, *Chlamydia trachomatis*, *Halobacterium* sp. NRC-1, *Mycoplasma capricolum*, *Neisseria gonorrhea*, *Pseudomonas aeruginosa*, *Pyrococcus furiosus*, *Pyrobaculum aerophilum*, *Rhodobacter capsulatus*, *Rhodobacter sphaeroides*, *Streptococcus pyogenes*, *Ureaplasma urealyticum*, *Crenarchaeum symbiosum*, *Pasteurella multocida*, *Ehrlichia* sp. (HGE agent), *Haemophilus ducrey* and *Streptomyces hygroscopicus*.

Exemplary eukaryotic organisms include: *Aspergillus nidulans*, *Candida albicans*, *Leishmania major*, *Neurospora crassa*, *Pneumocystis carinii*, *Plasmodium falciparum*, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Trypanosoma cruzi*, *Trypanosoma brucei*, *Tetrahymena* sp., *Cryptosporidium parvum*, *Arabidopsis thaliana* M, *Brugia malayi*, *Caenorhabditis elegans*, *Drosophila melanogaster*, *Shistosoma mansoni*, *Shistosoma japonicum*, and mammals, e.g., humans.

Targets can be produced by an organelle of a eukaryotic organism. For example, the target can be a mitochondrial enzyme. Examples of the organisms for which the genomes of organelles are known include: *Chlorarachnion*, *Guillardia theta*, *Cyanophora paradoxa*, *Epifagus virginiana*, *Euglena gracilis*, *Guillardia theta*, *Marchantia polymorpha*, *Nicotiana tabacum*, *Odontella sinensis*, *Oryza sativa*, *Porphyra purpurea*, *Pinus thunbergiana*, *Acanthamoeba castellanii*, *Allomyces macrogynus*, *Bos Taurus*, *Cafeteria roenbergensis*, *Chrysodidymus synuroideus*, *Chondrus crispus*, *Chlamydomonas reinhardtii*, *Drosophila melanogaster*, *Drosophila yakuba*, *Equus asinus*, *Homo sapiens*, *Mus musculus*, *Ochromonas danica*, *Porphyra purpurea*, *Prototheca wickerhamii*, *Reclinomonas Americana*, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Tetrahymena pyriformis* and *Xenopus laevis*.

Targets can also be produced by phage, including without limitation, *Acholeplasma* bacteriophage, *Acholeplasma* phage/virus, Bacteriophage bIL67, Bacteriophage Cp-1, Bacteriophage G4, Bacteriophage HP1, Bacteriophage IKe, Bacteriophage lambda, Bacteriophage MS2, Bacteriophage PRD1, Bacteriophage PZA, Bacteriophage T4 and *Lactococcus* bacteriophage C2.

Targets may also be viral proteins. Examples of the viruses that can produce the target include: Abelson murine leukemia virus, Adeno-associated virus 2, Adeno-associated virus 3, African swine fever virus, Alfalfa mosaic virus, Apple chlorotic leaf spot virus, Apple stem grooving virus, Arabis mosaic virus satellite, Arctic ground squirrel hepatitis B virus, Artichoke mottled crinkle virus, *Autographa californica* nuclear polyhedrosis virus, Avian carcinoma virus,

Avian infectious bronchitis virus, Avian leukosis virus, Avian sarcoma virus, BK virus, Baboon
 endogenous virus, Baboon endogenous virus (BaEV), Bamboo mosaic virus, Barley yellow dwarf
 virus, Barmah Forest virus, Bean golden mosaic virus, Beet curly top virus, Beet yellows virus,
 Black beetle virus, Bombyx mori nuclear polyhedrosis virus, Border disease virus, Borna disease
 5 virus, Bovine immunodeficiency virus, Bovine leukemia virus, Bovine viral diarrhea virus, Brome
 mosaic virus, Cacao swollen shoot virus, Caprine arthritis-encephalitis virus, Cardamine chlorotic
 fleck virus, Carrot mottle virus A, Cassava common mosaic virus, Cassava latent virus, Cassava
 vein mosaic virus, Cauliflower mosaic virus, Chicken anemia virus, Chloris striate mosaic virus,
 Citrus tristeza virus, Clover yellow mosaic virus, Coconut foliar decay virus, Commelina yellow
 10 mottle virus, Cucumber green mottle mosaic virus, Cucumber mosaic virus, Cucumber necrosis
 virus, Dengue virus 3, Dengue virus type 1, Dengue virus type 2, Digitaria streak virus, Duck
 hepatitis B virus, Ebola virus (constructed), Eggplant mosaic virus, Encephalomyocarditis virus,
 Equine infectious anemia virus, Feline immunodeficiency virus, Foxtail mosaic virus, Friend
 murine leukemia virus, Friend spleen focus-forming virus, Fujinami sarcoma virus, Ground squirrel
 15 hepatitis virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis D virus, Hepatitis E
 virus, Hepatitis G virus, Hepatitis GB virus B, Heron hepatitis B virus, Hog cholera virus, Human
 T-cell lymphotropic virus type 1, Human T-cell lymphotropic virus type 2, Human T-cell
 lymphotropic virus type I, Human adenovirus type 12, Human adenovirus type 2, Human foamy
 virus, Human herpesvirus 1, Human herpesvirus 3, Human herpesvirus 4, Human
 20 immunodeficiency virus type 1, Human immunodeficiency virus type 2, Human parainfluenza
 virus 3, Human respiratory syncytial virus, Infectious hematopoietic necrosis virus, Influenza A
 virus, Influenza B virus, Influenza C virus, JC virus, Japanese encephalitis virus, Jembrana disease
 virus, Kennedy yellow mosaic virus, Lactate dehydrogenase-elevating virus, Leishmania RNA
 virus, Leishmania RNA virus 1, Lucerne transient streak virus, Maize streak virus, Maize streak
 25 virus, Marburg virus, Mason-Pfizer monkey virus, Measles virus, Melon necrotic spot virus, Mice
 minute virus, Molluscum contagiosum virus subtype 1, Moloney murine sarcoma virus, Mouse
 mammary tumor virus, Murine leukemia virus, Murine osteosarcoma virus, Murine sarcoma virus,
 Mushroom bacilliform virus, Narcissus mosaic virus, O'nyong-nyong virus, Odontoglossum
 ringspot virus, Olive latent virus 1, Ononis yellow mosaic virus, Ovine pulmonary adenocarcinoma
 30 virus, Panicum streak virus, Papaya mosaic virus, Papaya ringspot virus, Pea early browning virus,
 Pea seed-borne mosaic virus, Peanut chlorotic streak virus, Peanut stripe virus, Peanut stunt virus,

Pepper huasteco virus, Pepper mottle virus, Plum pox virus, Polyomavirus strain a2, Polyomavirus strain a3, Potato leaf roll virus, Potato mop-top virus, Potato virus A, Potato virus M, Potato virus X, Potato virus Y, Punta Toro virus, Rabbit hemorrhagic disease virus, Rabies virus, Rice tungro spherical virus, Rice yellow mottle virus, Ross River virus, Rous sarcoma virus, Rubella virus, 5 Saccharomyces cerevisiae virus La, Saguaro cactus virus, Satellite tobacco necrosis virus, Sendai virus, Simian foamy virus, Simian immunodeficiency virus, Simian sarcoma virus, Simian virus 40, Sindbis virus, Sindbis-like virus, Sonchus yellow net virus, Southern bean mosaic virus, Soybean chlorotic mottle virus, Spiroplasma virus, Strawberry vein banding virus, Sulfolobus virus-like particle ssv1, Swine vesicular disease virus, Theiler's encephalomyelitis virus, Tick- 10 borne encephalitis virus, Tobacco etch virus, Tobacco mild green mosaic virus, Tobacco mosaic virus, Tobacco necrosis virus, Tobacco vein mottling virus, Tomato bushy stunt virus, Tomato golden mosaic virus, Tomato leaf curl virus, Tomato yellow leaf curl virus, Turnip vein-clearing virus, Turnip yellow mosaic virus, Vaccinia virus, Variola virus, Venezuelan equine encephalitis virus, Vesicular stomatitis virus, Visna virus, West Nile virus, Woodchuck hepatitis B virus, 15 Woodchuck hepatitis virus, Y73 sarcoma virus, and Yellow fever virus.

Bioinformatic Analysis of Targets

In preferred embodiments, a putative or predicted function is assigned to the target, preferably, prior to testing the target with a test compound. To assign a putative function to the 20 target, e.g., protein, several bioinformatic techniques can be used. The identification of a characteristic shared (or in some cases not shared) by the target and a molecule, e.g., a protein, of known function can allow assignment of the, or an, activity of the molecule, e.g., protein, of known function to the target. Examples of the methods currently used to predict protein functions include: sequence-based searches, fold recognition techniques (including threading algorithms and neural 25 networks), homology modeling, and structure-based analyses.

For example, using FASTA, BLAST and Smith-Watermann algorithms, a pairwise sequence comparison of a given sequence against all those with known function can be carried out (Shpaer, E.G. et al. (1996) Genomics 38(2)). To identify conserved regions of a protein, e.g., sequence motifs that may be predictive of function, two techniques can be used: PROSITE 30 [<http://expasy.hcuge.ch/sprot/prosite.html>] and BLOCKS [<http://www.blocks.fhcrc.org/blocks/>]. PROSITE analysis relies on matching patterns of amino acid residues using a consensus sequence

or motif. A second approach, BLOCKS, matches sequences against a full ungapped multiple sequence alignment of the conserved region not just the consensus sequence, and can therefore be highly sensitive at picking out distantly related sequences.

The target amino acid sequence can also be analyzed for the presence or absence of protein folds using the Class, Architecture, Topology (fold family) and Homologous superfamily (CATH) database [<http://www.biochem.ucl.ac.uk/bsm/cath>]. Currently, more than 670 different types of protein folds are represented in this database. The ability to predict these structural motifs from primary sequence can be improved through the use of threading techniques (i.e. fitting the amino acid sequence of a protein of interest along a known 3-dimensional protein structure) (Bryant, SH et al. (1993) *Proteins* 16: 92-112). Furthermore, neural networks can also be used to predict the fold of proteins (Bohr, H. et al. (1990) *FEBS Lett.* 261, 43-46).

Additional predictions of the accuracy of the function of a target protein which is homologous to another protein of known function (provided that at least 30-35% of the amino acid sequences are identical) can be obtained by homology modeling. Homology modeling (Johnson, MS et al. (1994) *Crit. Rev. Biochem. Mol. Biol.* 29:1-68) involves the use of computational algorithms to compare the amino acid sequence of a protein of interest with that of another related protein with known 3-dimensional structure.

Furthermore, structure-based determination of protein function can be used to infer a biological function for a target. For this analysis, the crystal structure of a target protein is determined, and its 3-dimensional structure is then compared with other proteins of known function. If there is a match, a biological function for a target can be predicted based on the known functions of the other protein. This approach was recently used to identify a novel NTPase from *Methanococcus jannaschii* (Hwang, KY et al. (1999) *Nat. Struct. Biol.* 6: 691-696).

Generation of Test Compounds

A test compound (an interactor) is a chemical compound, molecule or complex, which is can be tested for its ability to interact with (e.g., bind to) a target, e.g., a target protein. In one embodiment, the test compound is a small organic molecule, e.g., a synthetic or a naturally-occurring non-proteinaceous molecules. The test compound can be designed such that it interacts with a target, or it can be selected from a library of diverse compounds (e.g., a substrate library or a

combinatorial library) based on a desired activity, e.g., random drug screening based on a desired activity (e.g., its ability to interact with a target).

Libraries

5 Method of the invention use libraries as sources of candidate interactors, e.g., agents which are candidates to be tested for the ability to interact with a target. A library can include a plurality of structurally or functionally related members. Library members can, however, be unrelated by structure or function.

10 A library which includes a plurality of members which are functionally or structurally related can be useful, particularly when the target can be assigned an activity or a putative activity. For example, in the case where the target may be a nuclease, a nuclease substrate library can be tested against the target. A nuclease substrate library can include a range of substrates or putative substrates.

15 Libraries can be directed to broad target "activities". Examples of libraries are discussed below. The substrate requirements of newly discovered enzymes can be determined by dividing the substrate library in a systematic manner. This methodology will be referred to herein as substrate profiling.

Cofactor libraries

20 A "cofactor" library can include any of: group transfer and energy coupling molecules, coenzyme, e.g., ATP, GTP, TTP, CTP, UTP, NADH, NADPH, NAD, NADP, FAD, FADH, phosphoenolpyruvate, Coenzyme A, lipoamide, S-adenosylmethionine, Thiamine pyrophosphate, Biotin, tetrahydrofolate, Uridine diphosphate glucose, Cytidine diphosphate diacylglycerol, and all known CoA modifying molecules such as succinyl-CoA. These group of molecules, called,
25 cofactors are involved in vast number of diverse enzymatic reactions. An example of a cofactor library is disclosed and tested in Example 5 below, and includes the following members: ATP, GTP, CTP, TTP, UTP, NADH, NADPH, NAD, NADP, FAD, Flavin, Thiamine Monophosphate Chloride, Pyrodoxal 5'-phosphate, Coenzyme A, and Cocarboxylase.

30 In a preferred embodiment, the library includes at least 1, 2, 5 or 10 of the members disclosed herein. In many cases a cofactor library will be tested together with another library, for

example, a cofactor library can be tested in combination with a carbohydrate library (see Example 5, below).

Carbohydrate metabolism libraries

5 Carbohydrate metabolism libraries, e.g., biosynthesis and/or degradation libraries can be used to screen for carbohydrate modifying enzymes. They can include carbohydrates, e.g., those involved in known biochemical pathways including long, short and single unit carbohydrates and modified carbohydrates from known biochemical pathways such as phosphorylated carbohydrates. A library of this type can include carbohydrates or modified carbohydrates not yet known to be
10 substrates for any enzymes. Examples of the carbohydrates that can be used include: Glucose, Fructose, Arabinose, Xylose, Mannose, Galactose, Lactose, Sucrose, and Ribose. Additional examples of substrates which can be used in the carbohydrate library are provided in the Metabolic Pathway Chart, 1997, 20th edition, from Sigma-Aldrich. In a preferred embodiment, the library includes at least 1, 2, 5 or 10 of the members disclosed herein. The carbohydrate library can be
15 tested in combination with other libraries, e.g., a cofactor library.

An example of a carbohydrate library is disclosed and tested in Example 5 below, and includes the following members: D-glucose, arabinose, sucrose, ribose, lactose, galactose, maltose, and xylose tested.

20

Purine and pyrimidine metabolism libraries

Purine and pyrimidine metabolism libraries, e.g., biosynthesis and/or degradation libraries can include nucleoside/nucleotide precursors and can be used to screen for enzymes involved in purine and pyrimidine biosynthesis or degradation. Examples of the purine and pyrimidine
25 compounds that can be used include: Glycinamide-ribose-phosphate, Urea, Formyl glycinamide-RP, 5-Aminoimidazol carboxylate-RP, Inosine-P, Formylamido-imidazole-carboxamide-RP. Additional examples of substrates which can be used in the purine and pyrimidine library are provided in the Metabolic Pathway Chart, 1997, 20th edition, from Sigma-Aldrich. In a preferred embodiment, the library includes at least 1, 2, 5 or 10 of the members disclosed herein. The purine
30 and pyrimidine metabolism library can be tested in combination with other libraries, e.g., a cofactor library.

Amino acid metabolism libraries

Amino acid metabolism libraries, e.g., biosynthesis and/or degradation libraries can include amino acids, both D and/or L form, and precursors of the amino acids. It can include peptides with known protease domains to serve as substrates for all the currently known proteases. This library will also contain some non-enzymatic proteins such as BSA to test for proteolytic activity not yet discovered or categorized, allowing the discovery of new classes of proteases. Examples of the amino acids that can be used in the amino acid metabolism library include: Alanine, Aspartate, Cysteine, Histidine, Glycine, and Isoleucine. Additional examples of substrates which can be used in the amino acid metabolism library are provided in the Metabolic Pathway Chart, 1997, 20th edition, from Sigma-Aldrich. Examples of a peptide to be used as protease substrates include acetyl-ser-gln-asn-tyr-pro-val-val amide (from Sigma, page 1132, catalogue number A0806, 1999 edition) and Ser-pro-Arg also from Sigma. In a preferred embodiment, the library includes at least 1, 2, 5 or 10 of the members disclosed herein. The amino acid metabolism library can be tested in combination with other libraries, e.g., a cofactor library.

Lipid metabolism libraries

Lipid metabolism, e.g., a biosynthesis and/or degradation library, can include fatty acids, fatty acid precursors, steroids and steroid precursors, both those already discovered as substrates for known enzymes as well as fatty acids and steroids not yet discovered or categorized as substrates for enzymes. This library can be used to screen for enzymes involved in fatty acid metabolism. Examples of the substrates that can be used in the lipid metabolism libraries include: cholesterol, desmosterol, Zymosterol, Lanosterol, choline, lecitin, cephalin, linoleate, cardiolipin, and acetylcholine. Additional examples of substrates which can be used in the lipid biosynthesis and degradation library are provided in the Metabolic Pathway Chart, 1997, 20th edition, from Sigma-Aldrich. In a preferred embodiment, the library includes at least 1, 2, 5 or 10 of the members disclosed herein. The lipid metabolism library can be tested in combination with other libraries, e.g., a cofactor library.

Vitamin and hormone libraries

This class of library can include vitamins and hormones as well as their metabolic precursors and can be used to screen for enzymes involved in the synthesis, breakdown or modification of hormones of vitamins. Examples of the substrates that can be used in the vitamin and hormone library include: retinoate, metarhodopsin, rhodopsin, vitamin K, opsin, and vitamin E. Additional examples of substrates which will be used in the vitamin and hormone library are given in the Metabolic Pathway Chart, 1997, 20th edition, from Sigma-Aldrich. In a preferred embodiment, the library includes at least 1, 2, 5 or 10 of the members disclosed herein. The vitamin and hormone library can be tested in combination with other libraries, e.g., a cofactor library.

DNA molecule libraries

This class of library can be used to screen for DNA modifying enzymes. It can include ds and ss DNA molecules, as well as partially ds DNA molecules, and DNA of random sequence, such as calf thymus DNA. It can include covalently closed circular DNA, both supercoiled and relaxed. These DNA molecules can be obtained from commercial vendors such as Sigma, Amersham, and Biorad. In a preferred embodiment, the library includes at least 1, 2, 5 or 10 of the members disclosed herein. The DNA molecule library can be tested in combination with other libraries, e.g., a cofactor library.

Natural product libraries

Natural product libraries, e.g., bacterial natural product library can contain the natural products of an organism, e.g., a bacterium. They can be used to screen for unknown enzymatic activity amongst the unknowns. The substrate requirements of the natural product library can be determined by the deconvolution of the natural products by chromatographic methods. In a preferred embodiment, the library includes at least 1, 2, 5 or 10 of the members disclosed herein. The natural product library can be tested in combination with other libraries, e.g., a cofactor library.

In certain embodiments, the natural product, e.g., the bacterial natural product, is generated *in vivo*, e.g., by using a mutant organism (e.g., a temperature-sensitive bacterial mutant, or an

auxotroph) which accumulates a given metabolite when grown at non-permissive conditions, e.g., at non-permissive temperature, or in the absence of an essential nutrient. The accumulated metabolite can be then purified from the organism prior to testing.

Each of the different substrate libraries can be incubated with the target protein/proteins with the cofactor library at several different pH values and a common mixture of different salts in solution. Any enzymatic activity can be detected as a change in the heat output detected by the calorimeter. This will allow us to immediately categorize the broad type of enzymatic activity the new protein has. The precise substrate requirements can then be determined by dividing the substrate library systematically. Finally the substrate requirements and solution conditions for the newly discovered enzymes can be optimized, and important parameters such as the k_{cat} , K_M and/or k_D can be determined.

In other embodiments, the test compound can be a member of a combinatorial library. Combinatorial libraries can be synthesized using methods known in the art and as reviewed in, see, e.g., E.M. Gordon *et al.*, *J. Med. Chem.* (1994) 37:1385-1401 ; DeWitt, S. H.; Czarnik, A. W. *Acc. Chem. Res.* (1996) 29:114; Armstrong, R. W.; Combs, A. P.; Tempest, P. A.; Brown, S. D.; Keating, T. A. *Acc. Chem. Res.* (1996) 29:123; Ellman, J. A. *Acc. Chem. Res.* (1996) 29:132; Gordon, E. M.; Gallop, M. A.; Patel, D. V. *Acc. Chem. Res.* (1996) 29:144; Lowe, G. *Chem. Soc. Rev.* (1995) 309, Blondelle *et al.* *Trends Anal. Chem.* (1995) 14:83; Chen *et al.* *J. Am. Chem. Soc.* (1994) 116:2661; U.S. Patents 5,359,115, 5,362,899, and 5,288,514; PCT Publication Nos. WO92/10092, WO93/09668, WO91/07087, WO93/20242, WO94/08051).

Libraries of test ligands can be prepared according to a variety of methods known in the art. For example, a "split-pool" strategy can be implemented in the following way: beads of a functionalized polymeric support are placed in a plurality of reaction vessels; a variety of polymeric supports suitable for solid-phase peptide synthesis are known, and some are commercially available (for examples, see, e.g., M. Bodansky "Principles of Peptide Synthesis", 2nd edition, Springer-Verlag, Berlin (1993)). To each aliquot of beads is added a solution of a different activated amino acid, and the reactions are allowed to proceed to yield a plurality of immobilized amino acids, one in each reaction vessel. The aliquots of derivatized beads are then washed, "pooled" (i.e., recombined), and the pool of beads is again divided, with each aliquot being placed in a separate reaction vessel. Another activated amino acid is then added to each aliquot of beads. The cycle of synthesis is repeated until a desired length is obtained. The residues added at

each synthesis cycle can be randomly selected; alternatively, residues can be selected to provide a "biased" library. It will be appreciated that a wide variety of peptidic, peptidomimetic, or non-peptidic compounds can be readily generated in this way.

In another illustrative synthesis, a "diversomer library" is created by the method of Hobbs DeWitt *et al.* (*Proc. Natl. Acad. Sci. U.S.A.* 90:6909 (1993)). Other synthesis methods, including the "tea-bag" technique of Houghten (see, e.g., Houghten *et al.*, *Nature* 354:84-86 (1991)) can also be used to synthesize libraries of compounds according to the subject invention.

Combinatorial libraries of compounds can be synthesized with "tags" to encode the identity of each member of the library (see, e.g., W.C. Still *et al.*, U.S. Patent No. 5,565,324 and PCT Publication Nos. WO 94/08051 and WO 95/28640). In general, this method features the use of inert, but readily detectable, tags, that are attached to the solid support or to the compounds. When an active compound is detected (e.g., by one of the techniques described above), the identity of the compound is determined by identification of the unique accompanying tag. This tagging method permits the synthesis of large libraries of compounds which can be identified at very low levels.

Such a tagging scheme can be useful to identify compounds released from the beads.

In preferred embodiments, the libraries of test ligands contain at least 30 compounds, more preferably at least 100 compounds, and still more preferably at least 500 compounds. In preferred embodiments, the libraries of test ligands contain fewer than 10^9 compounds, more preferably fewer than 10^8 compounds, and still more preferably fewer than 10^7 compounds.

Formats

The methods taught herein can be performed in a number of physical formats. In a preferred embodiment, the measurement is performed in an isothermal titration calorimeter. The calorimeter, e.g., an isothermal titration calorimeter, can be equipped with a flow cell. In a preferred embodiment the target is immobilized in the flow cell. Samples can be introduced into a flow cell from a multi-compartment sample holder, e.g., a multi-well plate such as a microtitre plate, e.g., a 96 well plate. Samples can be pre-mixed in the compartments of the sample holder.

In other preferred embodiments a multi-compartment sample holder, e.g., a multi-well plate such as a microtitre plate, e.g., a 96 well plate, in which each compartment includes a thermopyle, and each is a calorimetric cell can be used. Channels for fluid delivery to the compartments can be included.

In a preferred embodiment a method can be performed on a microchip, in which the appropriate wells channels, and other components have been formed, e.g., by etching or deposition. Fluids could be pumped or moved by electrokinetic methods.

In methods described herein the reaction mixture can include a single target or multiple targets. Similarly, one, or more, ligand can be added to a reaction mixture. It may be useful to multiplex one or both of these elements in order, e.g., to screen large numbers of species. E.g., where a large number of ligands are to be evaluated, the initial group of candidates can be pooled, and if a pool shows a promising result, members of the pool evaluated. Likewise in methods for evaluating substrates, candidates can be pooled.

For large scale screening, calorimetry can be combined with a high-throughput screening format. For the purposes of high-throughput screening, the experimental conditions described above are adjusted to achieve a threshold proportion of test ligands identified as "positive" compounds or ligands from among the total compounds screened. Preferably, this threshold is set according to two criteria. First, the number of positive compounds should be manageable in practical terms. Second, the number of positive compounds should reflect ligands with an appreciable affinity towards the target protein. A preferred threshold is achieved when 0.1% to 1% of the total test ligands are shown to be ligands of a given target.

ITCs are commercially available and are used routinely by skilled artisans. See e.g., US 5,873,763 issued to Plotnikov, V.V. on September 29, 1998; Indyk et al. (1998) *Meth. Enzymol.* 295:350-364; Brandts et al. (1990) *American Laboratory* 30-41. The ITC is a twin-cell differential device. It operates at a fixed temperature, while the liquid in the sample is continuously stirred. This instrument measures the heat that is evolved or absorbed as a result of the binding of the test ligand to the target.

In other embodiments, a differential scanning microcalorimeter (DSC) can be used to detect the heat output. DSCs are commercially available and are used routinely by skilled artisans. See e.g., US 5,873,763 issued to Plotnikov, V.V.; and Freire (1995) *Meth. Mol. Bio.* 40:191-218. The differential scanning microcalorimeter automatically raises or lowers the temperature at a given rate while monitoring the temperature differential between cells. From the temperature differential information, small differences in the heat capacities between the sample cell and the reference cell can be determined and attributed to the test substance.

In a preferred embodiment: the reaction mixture is not transparent; the reaction mixture is colored; the reaction mixture is turbid; the reaction mixture contains a substance which interferes with fluorescent or colorimetric detection; the reaction mixture is not a pure solution, e.g., it contains products other than the target. In a preferred embodiment the reaction mixture contains: a substance which interferes with radioactive analysis; a substance which interferes with spectrophotometric analysis, e.g., NMR analysis. In a preferred embodiment a complex mixtures of substances, e.g., an impure sample, such as a suspension, natural product extract, cell extract, biochemical mixture, or colored solution, which may include more than one test compounds, is tested.

Surrogate Ligand-Based Methods

Identification of Surrogate Nucleic Acid Ligands

A surrogate ligand can be a nucleic acid (e.g., an oligonucleotide). The SELEX procedure can be used to identify a surrogate ligand. Using the SELEX procedure (Gold et al. (1995) *supra*), a large number of random sequence oligonucleotides can be tested for their ability to bind with high affinity to a target, e.g., a target protein. The larger the library of nucleotides, the greater the chance of finding at least one sequence which binds to the target with a dissociation constant in the picomolar to nanomolar range. Preferably, the ligand is about 20 nucleotides in length, as longer oligonucleotides will presumably only bind using a fraction of their length, leaving some residues vulnerable to degradation or processing by a signal-generating entity, even while the ligand is bound to the target. For example, in the case of a surrogate nucleic acid ligand, longer oligonucleotide sequence may lead to background hydrolysis when a DNase is used.

In one embodiment, the target used in the methods of the invention is a protein (e.g., a target protein). Initially, the target protein can be identified and purified, using standard biochemical techniques such as HPLC and ion-exchange or size-exclusion chromatography. Preferably, a highly purified sample of the target protein is obtained. Then, the SELEX method is employed to identify a single-stranded oligonucleotide (DNA) ligand which binds to the protein with high (>nM) affinity. The first step in this process entails the generation of a random oligonucleotide library of 10^{14} - 10^{15} single-stranded DNA sequences which having the structure from the 5' to the 3' end shown below:

Fixed A Random Sequence Fixed B
5' ----- 3'

where Fixed A and B refer to constant sequences present at the 5' and the 3' ends of each member of the library. These constant sequences flank a random sequence and allow transcription and subsequent pool amplification after each round of the SELEX process (*see* Tuerk & Gold (1990) *Science* 249:505-510). Preferably, the random sequences should not range beyond 20 nucleotides in length, (as larger ligands may only bind to the target using a central span of their residues, thus leaving their termini exposed to the activity of the DNase even while they are still bound to the target protein).

Next, the library is mixed with the target protein and then partitioned by passage through a nitrocellulose membrane. Those DNA sequences bound to the filter by the protein are then eluted and amplified with the polymerase chain reaction (PCR) for subsequent transcription of the (now-modified) library for a second round of SELEX. The process is repeated until a ligand which binds with the desired affinity is obtained.

It has been shown that each round of the method produces on average a 10-fold enrichment of the high affinity ligands (Schneider *et al.* (1992) *J. Mol. Biol.* 228:862-869), and a range of between 10 and 20 rounds of SELEX are usually necessary to identify a ligand which binds with a K_d in the nanomolar range (Gold *et al.*, 1995, *supra*). In the initial rounds, it is advisable to use a fairly high amount of protein to insure the retention of all the high-affinity ligands when far more abundant low-affinity ligands are present in the library. The selectivity of the SELEX process can be increased by using lower amounts of the target (e.g., target protein) in the later rounds, when the high-affinity ligands have been enriched enough to survive the competitive binding situation. The process has been tried with over 30 proteins and in almost all cases oligonucleotide ligands were found which bound with greater than nM affinity (Gold *et al.*, 1995, *supra*).

Selection of The Signal-Generating Entity

Once a surrogate ligand has been identified, a suitable signal-generating entity is chosen which has high specific activity against the surrogate ligand. Preferably, the signal-generating entity interacts (e.g., binds) more readily with a free surrogate ligand, as opposed to a surrogate ligand bound to a target. Preferably, such interaction amplifies a signal, e.g., generates a heat

signal. In certain embodiments, the signal-generating entity modifies the free surrogate ligand by, e.g., forming or breaking a covalent or a non-covalent bond. For example, the modification step may involve cleavage, degradation, phosphorylation, polymerization, or any other event that generates a signal, e.g., a heat signal. The signal-generating entity can be a degradative enzyme (e.g., a nuclease or a protease). Alternative, the signal-generating entity can be a polymerizing enzyme, e.g., a polymerase.

The signal-generating entity can be immobilized, e.g., attached to a solid support, or crosslinked. For example, in those embodiments where the signal-generating entity is an enzyme, the enzyme can be cross-linked to form a crystalline enzyme.

For example, in those embodiments where the free surrogate ligand is a DNA molecule, the signal-generating entity can be a nuclease. Exemplary nucleases that can be used include without limitation staphylococcal nucleases (SNase), *Serratia marcescens* nucleases (SNase), bovine pancreatic nucleases (DNase I), or human (type IV) nucleases. As the activity can vary over many orders of magnitude, even for a single nuclease and a variety of oligonucleotide substrates, the optimal DNase may be chosen. Optimal solution conditions may also be chosen, e.g., pH, temperature, and solvent conditions. The activity of a particular DNase for a specific surrogate ligand can be assayed using methods described in Friedhoff et al. (1996) *Eur. J. Biochem.* 241:572-580 and Friedhoff et al. (1999) *FEBS Lett.* 443:209-214. Several exemplary DNases are listed in the table below, along with their activities against particular substrates. The table is by no means complete, and it is not intended to limit the scope of the present invention.

Table 1. Steady-state parameters for the cleavage of various nucleic acid substrates by several nucleases.

5	Enzyme	Substrate	k_{cat}/K_m ($s^{-1}\mu M^{-1}$)	Reference
	SNase ^a	salmon sperm DNA	15	Poole et al. (1991) <i>Biochemistry</i> 30:3621-3627
10	Dnase I ^b	calf thymus DNA	1.6	Doherty et al. (1995) <i>J. Mol. Biol.</i> 251(3):366-77
	SM6 ^c	salmon testis DNA	54	Friedhoff et al. (1996) <i>supra</i>
	BNase ^d	salmon DNA	7.2	Brown & Ho (1987) <i>Eur. J. Biochem.</i> 168:357-364

15

^a staphylococcal nuclease^b bovine pancreatic desoxyribonuclease^c *Serratia Marcescens* endonuclease20 ^d barley nuclease

The signal-generating entity can also be a polymerase, e.g., a Tac polymerase. In those embodiments, where the free surrogate ligand is an RNA molecule, the signal-generating entity can be a ribonuclease (e.g., an RNase).

25 In other embodiments where the free surrogate ligand (as opposed to target-bound) is a protein or a peptide, the signal-generating entity can be a protease. Proteases useful in practicing the present invention include without limitation trypsin, chymotrypsin, V8 protease, elastase, carboxypeptidase, proteinase K, thermolysin and subtilisin (all of which can be obtained from Sigma Chemical Co., St. Louis, Mo.). The most important criterion in selecting a protease or

30 proteases for use in practicing the present invention is that the protease(s) must be capable of digesting the particular target protein under the chosen incubation conditions. To avoid "false positive" results caused by test ligands that directly inhibit the protease, more than one protease, particularly proteases with different enzymatic mechanisms of action, can be used simultaneously or in parallel assays. In addition, cofactors that are required for the activity of the protease(s) are

35 provided in excess, to avoid false positive results due to test ligands that may sequester these factors.

Calorimetric Ligand Screening Using a Surrogate Nucleic Acid

The description below exemplifies the use of a surrogate nucleic acid ligand and a target protein. The experimental conditions described herein can be easily extended to the use of other surrogate ligands (e.g., protein ligands) and targets by the skilled artisan. Briefly, once a surrogate ligand (e.g., a surrogate nucleic acid ligand) is identified which binds to the target protein with a suitable dissociation constant, a solution of the target protein and the surrogate nucleic acid ligand is prepared in a 1:1 ratio (concentrations approximately 10 nM) and allowed to equilibrate inside the microcalorimetry cell for several minutes, along with a much smaller concentration of a signal-generating entity. For example, a specific deoxyribonuclease (DNase), at a concentration of approximately 1 nM, which has been chosen for its high activity against the surrogate nucleic acid ligand identified in the SELEX process. One assumption in the present invention is that while the surrogate nucleic acid ligand is bound to the target protein, it is prevented from undergoing as rapid a degradation by the DNase as the free surrogate nucleic acid ligand.

More specifically, the target protein, surrogate nucleic acid ligand, and specific nuclease are then combined together in solution to form a reaction mixture. The target protein and surrogate nucleic acid ligand can both be present at approximately 1 μ M, while the nuclease is present at approximately 1 nM. The total sample volume is approximately 1 ml. The sample is incubated in the microcalorimetry cell (e.g., the cell of an isothermal titration calorimeter). The twin cells are housed in an insulated container. The container is cooled, so heat energy is required to maintain the cells and their contents at the experimental temperature. The two cells are kept at thermal equilibrium with each other. A small aliquot (5-25 μ l) of a test ligand that potentially binds to the target protein is then added to the sample cell. If the test ligand binds to the target protein with significant affinity (relative to the oligonucleotide), it will release some fraction of the surrogate ligand into solution, depending on the magnitudes of the respective binding constants. This newly-liberated surrogate ligand will then begin to be hydrolyzed by the nuclease present in the solution, thus generating a heat output (power output) much larger than that produced by the initial competitive binding of the test compound. The heat output can be recorded for approximately 1 minute. The total heat output for a given trial can be related to (e.g., is proportional to) the ratio of the affinities of the surrogate ligand and the test ligand for the target protein.

In other embodiments, the conformational change of a target upon test ligand binding can be measured. Protein targets and structured RNA targets (e.g., ribozymes) have one common

feature: they undergo a conformational change to a less compact form upon addition of a denaturant to the solution, or when heat is added by an increase in temperature. The conformational change that a protein or RNA undergoes is accompanied by a large change in heat that may conveniently be detected by a calorimeter. If a test ligand binds to the more compact form of the target protein or RNA, then it will inhibit the conformational change thereby allowing for a difference in heat output to be detected as compared to a control solution with no test ligand. A detailed description of this detection is provided in Examples 3 and 4.

The methods can also be used to analyze (e.g., identify) agents that bind to a target where the target is present on the surface of a cell, e.g., a bacterial cell wall component. Thus, the methods can be used to identify agents that interact with (e.g., bind to) cell surface molecules.

The interaction among the target and the surrogate ligand, test ligand, and/or substrate can occur *in vitro* (e.g., in a cell-free system), or *in vivo* (e.g., in a cell, e.g., a prokaryotic or an eukaryotic cell). For example, this interaction can be tested by adding these compounds to cells, e.g., living cells, placed inside of a calorimeter.

In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are set forth for illustrative purposes only and are not to be construed as limiting this invention in any manner.

EXAMPLE 1: SCREENING FOR COMPOUNDS CAPABLE OF BINDING TO A TARGET PROTEIN

First, a single-stranded oligonucleotide of DNA is identified which binds to the target protein of interest with high affinity. For the purpose of this example, the ligand is assumed to be 20 residues long and has a $k_d = 1$ nM. The protein and the oligonucleotide ligand are mixed together, each with a concentration of 10 μ M. A minute amount (1 nM) of a deoxyribonuclease known to have high activity against the ligand is added (total volume of the solution 500 μ l). The binding reaction between the target protein (P) and the ligand (L) can be written as follows:

K_d

$$PL = P+L \quad \text{and rearranged in the form: } K_d = \frac{[P][L]}{[PL]} \quad (\text{equation 1})$$

Knowing the concentration of the protein-ligand complex [PL] allows the calculation of the amount of free protein and free ligand in the solution, from the expressions

$$[P_T] = [P] + [PL] \quad (\text{equation 2}) \quad \text{and} \quad [L_T] = [L] + [PL] \quad (\text{equation 3})$$

Substituting equations 2 and 3 into equation 1 and solving for [PL] gives the quadratic expression:

$$[PL]^2 - (L_T + P_T + K_d) [PL] + P_T L_T = 0$$

which can be solved for [PL]. In this case, where $[P_T]$ and $[L_T]$ are both 10 μM and $K_d = 1 \text{ nM}$, [PL] is equal to 0.99 μM , which means that 1% of the ligand is free in solution (from equation 3). This small fraction will begin to be hydrolyzed once the protein-ligand solution is combined with the DNase (giving some baseline heat output: $70 \mu\text{cal/sec} \times 10 \text{ sec}^{-1} = 700 \mu\text{cal/sec}$).

After the initial solution of target protein, ligand, and nuclease is allowed to equilibrate in the sample cell, a test compound is added, at a final concentration of 10 μM . Assuming for the purposes of this example that it has an identical K_d for the target as the original oligonucleotide, the test compound will eventually compete off one-half of the DNA, leaving it to be degraded by the DNase. The total amount of DNA in the cell is approximately 5×10^{-9} moles. If half of this is hydrolyzed completely, this means that $(20)(2.5 \times 10^{-9}) = 5 \times 10^{-8}$ moles of phosphodiester bonds are cleaved, giving a total heat output of $(70 \text{ kcal/mol})(5 \times 10^{-8} \text{ mol})(10 \text{ sec}^{-1}) = 35,000 \mu\text{cal/sec}$. This is a factor of 50 larger than the baseline heat output from the original 1% free ligand.

EXAMPLE 2: CALORIMETRIC DETECTION OF ENZYMATIC TURNOVER AND INHIBITION

The measure of activity of an enzymatic reaction is directly proportional to the differential power output in the calorimetric cell resulting from catalyzed conversion of substrate to product. The detection signal (power) for an enzyme reaction, as monitored by a calorimeter, is equal to the substrate turnover per second times the heat of the reaction, as given by the following equation:

$$\Delta P = \Delta H \times V = \Delta H [-dS/dt]$$

where S is the substrate concentration and V is the enzymatic rate.

To measure changes in enzyme activity that are as small as 5%, the change in power output of the calorimeter need be no greater than 0.5 μ cal/sec. This power change would result from substrate turnover of 5×10^{-11} moles/sec assuming a typical heat of reaction of 10 kcal/mol of substrate. Since turnover numbers for enzymes are in the range from 10 to 10,000 per second, one would only require as little as picomoles or femtomoles of enzyme in the calorimeter to perform each drug screening assay.

To optimize the calorimetric assay to ensure maximum signal change, it is helpful to consider the following. A simple form of the equation relating velocity of an enzyme to the concentration of substrate and inhibitor is:

$$V = V_{\max} \{1 + K_m/S [1 + I/K_i]\}^{-1}$$

where S and I are the substrate and inhibitor concentrations, respectively, K_i is the inhibitor dissociation constant and K_m is the Michaelis-Menton parameter for substrate. K_m values vary predominantly in the range from 10^{-1} to 10^{-6} M. The enzyme activity is most sensitive to changes in small concentrations of inhibitor when the substrate concentration equals the K_m . Addition of an inhibitor at a concentration equal to K_i , to a solution of enzyme with substrate concentration K_m reduces the velocity of the enzyme (and hence the power output) by 34%.

EXAMPLE 3: DETECTION OF A TEST LIGAND BY MEASURING THE HEAT OF CONFORMATION CHANGE OF A TARGET USING AN ISOTHERMAL CALORIMETER

After purifying the target of interest (e.g., a target protein or structured RNA), a solution of a buffered solution is denaturant such as Guanidine hydrochloride or urea is introduced into the calorimetric reaction cell. Then a syringe is filled with protein at a specified concentration (- 100

μM). Injections of approximately 10 μL (containing 1 nanomole of target) are introduced into the calorimetric cell. For a typical protein, 100 kcal/mol is absorbed when the protein undergoes its conformational change to a less compact state, so that 100 microcalories can be detected, after subtracting out any heat effect due to the dilution of the denaturant. The heat effect due to the dilution of the denaturant will be small since 10 μL titrant are being added to over 1000 μL of solution. However, the actual value for this dilution effect can be determined by adding 10 μL of buffer without protein into the solution of denaturant.

In order to detect if a test ligand binds to the protein, one can repeat the above experiment, modifying it so that the test ligand is introduced into the denaturant solution and the protein solution at equal concentrations. If the test ligand binds to the compact state of the protein, then a smaller amount of the protein will convert to the less compact state upon being injected into the calorimeter, leading to a change in the overall heat output. The injection process could easily be automated by coupling a flow injection system to a titerplate, so that each sample is introduced into the same larger volume of denaturant.

EXAMPLE 4: DETECTION OF A TEST LIGAND BY MEASURING THE HEAT OF CONFORMATION CHANGE OF A TARGET USING A DIFFERENTIAL SCANNING CALORIMETER

A buffered solution containing a purified target (e.g., a target protein of interest) is introduced into the differential scanning calorimeter reaction cell. Heat is added by increasing the temperature of the solution. When the protein undergoes its conformational change to a less compact form, heat is released. The apparent specific heat capacity curve is integrated to obtain the apparent specific heat output due to the conformational transition. The experiment is repeated with a fresh solution of protein to which some test ligand has been added. If the test ligand binds to the protein, the apparent specific heat output obtained by integrating the apparent specific heat capacity curve between the same two temperature points as the previous experiment, will be less. This difference serves as a convenient signal to indicate which ligands bind to the protein.

EXAMPLE 5: HEXOKINASE SUBSTRATE PROFILING EXPERIMENT

This example shows the monitoring of the rate of heat production resulting from the phosphorylation of glucose by hexokinase using isothermal titration calorimetry (ITC).

Materials and Methods:

Hexokinase type F-300 from Bakers yeast was purchased from Sigma and used without further purification. ATP and the carbohydrate and coenzyme kits used for substrate profiling were also obtained from Sigma. All reagents were suspended in a solution containing 100mM HEPES (pH 8.0), 10 mM MgCl₂, 10mM KCl and 1mM in ATP (reaction buffer). In order to create multiple combinations of carbohydrate and coenzyme mixtures (see flow chart below), stock solutions for each individual component were made up to 2 and 1mM respectively, such that final dilution's with the reaction buffer yielded 1mM carbohydrate and 0.5 mM coenzyme. Hexokinase was prepared as a 50-unit/ml stock solution in reaction buffer.

Reaction enthalpies reflecting enzyme turnover were obtained from thermograms collected with a VP-ITC microcalorimeter (MicroCal Inc., Northampton, MA). The VP-ITC instrument directly measures the heat evolved or absorbed in liquid samples as a result of injecting precise amounts of reactants into a thermally equilibrated reaction cell. The reaction cell volume is approximately 1.7 mls and is enclosed with an identical reference cell in an adiabatic inner shield inside an adiabatic outer shield. Once the instrument has been completely assembled with a spinning syringe it is brought to the desired experimental temperature. As the cells reach thermal equilibrium, temperature differences between the reference cell and the sample cell are measured. Calibration of the differential power (DP signal) between the reference cell and the sample cell is obtained electrically by administering a known quantity of power through a resistive heating element on the cell. An injection which results in the chemical evolution (exothermic) or absorption of heat (endothermic) within the sample cell causes a negative change in the DP signal for an exothermic reaction and a positive change in the DP signal for an endothermic reaction. Since these chemical changes result in heats that deflect the initial (electrically equilibrated) DP signal away from equilibrium the instrument's DP feedback readministers power back into the cell compensating for these changes. Thus, the DP signal display has units of power ($\mu\text{cal/sec}$) and the time integral of the peak yields a measurement of thermal energy, ΔH .

The reaction conditions for the hexokinase substrate profiling were as follows: the sample cell was filled with 2 mls of the substrate/coenzyme solution described above. The assay was initiated by injecting 6 μ L of 50-Unit/ml hexokinase solution into the sample cell. The temperature during each calorimetric assay was held constant throughout each experiment at 25°. Under the conditions of the experiments represented here, heats of dilution and mixing (as measured by the heat evolved in the absence of substrate) were less than 5% of the total heat measured for the enzymatic reaction (see Figures 3B). Throughout the enzymatic reaction the rate of heat generated was monitored continuously as shown in Figures 3A-3B. The heat flow reaches a maximum soon after the addition of enzyme to the reaction cell and then decays to the baseline as the level of substrate is depleted (see Figure 3A). As can be seen from Figures 3A and 3B, the amount of heat generated directly reflects whether substrate is present or not.

The actual experimental protocol is summarized by the flow chart shown in Figure 4. For example, in the first experiment hexokinase is injected into the complete carbohydrate library. The carbohydrate library used contained: D-glucose, arabinose, sucrose, ribose, lactose, galactose, maltose, and xylose tested in the presence of a cofactor library, which included, ATP, GTP, CTP, TTP, UTP, NADH, NADPH, NAD, NADP, FAD, Flavin, Thiamine Monophosphate Chloride, Pyridoxal 5'-phosphate, Coenzyme A, and Cocarboxylase.

A heat signal is observed similar to that shown in Figure 3A. This signal is indicative of enzyme turnover and hence the presence of substrate. For the next set of experiments, the complete carbohydrate library is divided into two – one with substrate (Carbohydrate library 2A) the other without (Carbohydrate library 2B) (Figure 4). The experiment is repeated as before and this time only one sample generates a heat signal, that of Carbohydrate library 2A. Since no detectable heat signal is observed for Carbohydrate library 2B (see Figure 4) this collection is discarded. Next, we divided the Carbohydrate library 2A into two. The experiment is repeated as before, once again only one sample generates a heat signal. The sample containing substrate is divided in half again and the whole process is repeated, until by the process of elimination we arrive at a single component sample that contains the proper enzyme substrate – glucose.

All of the above-cited references and publications are hereby incorporated by reference.

Other embodiments are within the following claims.

What is claimed is:

1. A method of analyzing a target comprising:

- (1) assigning a putative function to the target;
- (2) providing a library of interaction candidates;
- 5 (3) providing a reaction mixture which includes the target;
- (4) contacting the target with a member of the library,
- (5) evaluating a change in heat output of the reaction mixture;
- (6) optionally, comparing the value for heat change obtained with a predetermined

value,

10 thereby analyzing the target.

2. The method of claim 1, further comprising repeating steps (3)-(6) with a second library member.

15 3. The method of claim 1, wherein analyzing includes identifying a library member which is a substrate or a ligand of the target.

4. The method of claim 1, wherein the target is a naturally occurring protein or fragment thereof.

20 5. The method of claim 1, wherein the target is a nucleic acid.

6. The method of claim 1, wherein the library of interaction candidates comprises a plurality of members, each of which is known to interact with the target having the assigned
25 putative function.

7. The method of claim 1, wherein the library of interaction candidates comprises at least 10, 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , or 10^8 compounds.

30 8. The method of claim 1, wherein the library of interaction candidates comprises a plurality of members having a common structural or functional characteristic.

9. The method of claim 1, wherein the library of interaction candidates is selected from the group consisting of a substrate library, a cofactor library, a carbohydrate library, a purine and pyrimidine library, an amino acid library, a lipid library, a vitamin and hormone library, a nucleic acid library and a natural product library.

10. The method of claim 1, wherein a member of the library of interaction candidates is selected from the group consisting of: an enzyme substrate, a metabolite, a cofactor, a natural product, a carbohydrate, a polysaccharide, a nucleic acid, an amino acid, a vitamin, a hormone, a lipid, a small organic molecule, a metal, a peptide, a protein, a lipid, a glycoprotein, a glycolipid, a transition state analog and combinations thereof.

11. The method of claim 1, further comprising testing the target against at least one member of a second library.

12. The method of claim 11, wherein the testing of the first and second libraries occurs simultaneously.

13. The method of claim 11, wherein the target modifies a member of the library.

14. The method of claim 1, wherein the change in heat output is measured with a microcalorimeter.

15. A library of interaction candidates, comprising at least one member which interacts with a target in a manner that produced a heat output.

16. The library of claim 15, which is selected from the group consisting of a substrate library, a cofactor library, a carbohydrate library, a purine and pyrimidine library, an amino acid library, a lipid library, a vitamin and hormone library, a nucleic acid and a natural product library.

17. The library of claim 15, which comprises a plurality of members having a common characteristic or function.
18. The library of claim 17, wherein all members of the plurality are enzyme cofactors, or
5 substrates for biosynthetic or degradative enzymes.
19. The library of claim 15, which comprises at least 10, 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , or 10^8 compounds.
- 10 20. The library of claim 15, wherein said member is selected from the group consisting of an enzyme substrate, a metabolite, a cofactor, a natural product, a carbohydrate, a polysaccharide, a nucleic acid, an amino acid, a vitamin, a hormone, a lipid, a small organic molecule, a metal, a peptide, a protein, a lipid, a glycoprotein, a glycolipid, and a transition state analog.
- 15 21. Apparatus for analyzing a biomolecular target, comprising:
a calorimeter for evaluating a change in heat of a reaction mixture comprising at least one biomolecular target contacting at least one interaction candidate.
22. The apparatus of claim 21, wherein the calorimeter comprises a microcalorimeter.
- 20 23. The apparatus of claim 22, wherein the microcalorimeter comprises a differential scanning microcalorimeter.
24. The apparatus of claim 21, wherein the calorimeter comprises an isothermal titration
25 calorimeter.

25. The apparatus of claim 21, wherein the calorimeter comprises a reaction vessel for holding polymeric beads carrying at least one interaction candidate.

26. The apparatus of claim 21, wherein the calorimeter comprises a molecular detection
5 switch.

27. The apparatus of claim 1, wherein the calorimeter comprises a flow cell.

28. The apparatus of claim 21, wherein the calorimeter comprises a sample holder having a
10 plurality of compartments.

29. The apparatus of claim 28, wherein each said compartment comprises a calorimetric cell and a thermopyle.

30. The apparatus of claim 29, wherein the calorimeter further comprises channels for fluid
15 delivery to said plurality of compartments.

31. The apparatus of claim 30, wherein the calorimeter further comprises channels for fluid
20 delivery from said plurality of compartments.

32. The apparatus of claim 31, wherein the compartments are channels for fluid delivery are
formed in a microchip.

33. The apparatus of claim 28, wherein the sample holder comprises a multi-well plate.
25

34. The apparatus of claim 33, wherein said multi-well plate comprises a microtitre plate.

35. The apparatus of claim 34, wherein said microtitre plate comprises a 96 well plate.

36. The apparatus of claim 21, wherein the calorimeter comprises an artificial neural network.

5

37. The apparatus of claim 21 wherein the calorimeter comprises a twin-cell differential device.

1 / 12

FIG. 1






FIG. 2



2 / 12

FIG. 3A

6 μ l hexokinase injected into
carbohydrate library with substrate

**FIG. 3B**

6 μ l of Hexokinase injected into
Carbohydrate library minus substrate





FIG. 4



4 / 12

FIG. 5a(i)




FIG. 5a(ii)




FIG. 5b





FIG. 6
Thrombin + SAR-PRO-ARG-PNA



7 / 12






FIG. 7B



9 / 12



10 / 12





FIG. 7D

11/12

FIG. 8

12 / 12

FIG. 9

